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Summary 
Background: Stillbirth or intrauterine fetal death (IUFD) is a severe and difficult event for the 
parents and occurs in approximately five of 1000 births in high-income countries. Understanding 
of causes and recognition of risk factors is essential for preventive measures, counseling of 
parents, surveillance of health care and comparison both nationally and internationally.
Objectives: To estimate the incidence of stillbirths in a Norwegian population, classify according 
to cause of death, investigate socio-demographic, clinical and thrombophilic risk factors and to 
evaluate variations in risk estimates by different control selection.
Methods: 377 women with IUFD after 22 gestational weeks at two university hospitals in the 
Oslo area, in the period 1990 to 2003, were classified according to the Cause Of Death and 
Associated Conditions (CODAC) classification of perinatal deaths. They were compared with 
two different control-groups for the identification of socio-demographic and clinical risk factors. 
A subsample of 105 cases and 262 controls comprised the study population for acquired and 
inherited thrombophilic risk factors. 
Results: The incidence of stillbirths was 4.1 per 1000 deliveries. The majority (68%) had 
placental pathology as a main cause of death or as an associated condition. Small for gestational 
age (SGA) and placental abruption were strongly associated with IUFD, but hypertensive 
disorders were moderate risk factors if not mediated through SGA. Other risk factors were of low 
prevalence and of limited importance in the prevention of IUFD. Risk factors differed according 
to cause, apart from smoking and SGA that were risk factors in all causal groups. Lupus 
anticoagulant was associated with a history of IUFD, although probably confined to women with
multiple positivity for antiphospholipid antibodies. The prothrombin gene G20210A 
polymorphism was also associated with IUFD, most prominent in the group of placental causes.
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1.     Introduction 
In high-income countries the population in general expects that every pregnancy will lead to the 
birth of a healthy baby. The perception is that stillbirths are something of the past. However, 
although the rates of stillbirths have fallen remarkably over the past 50-60 years, they are still not 
rare events and are devastating for the parents. Identification of causes and risk factors is 
necessary for stillbirth prevention. Scandinavian studies on stillbirth ((intrauterine fetal death 
(IUFD)), have most often focused on a single or limited number of risk factors and the studies 
addressing multiple risk factors have reported on either unexplained IUFD only [1], or on 
perinatal mortality [2,3] and not on stillbirths in general. This accounts also for available 
epidemiological data from Norway.
Classifying stillbirths according to cause is needed for the purpose of prevention, counseling 
and comparison. In addition risk factors may vary between different causal groups. However, 
assigning a single cause of death is challenging and the use of suboptimal classification systems 
may contribute to a higher proportion of unexplained deaths.
Previous to this study there were no data from Norway on the association of acquired or 
inherited thrombophilia and IUFD. Studies investigating the association between inherited 
thrombophilias or antiphospholipid antibodies (APAs) and IUFD have often been of small 
sample size [4-6], and they have differed in selection criteria for cases and controls [7,8]. In 
addition, investigators reporting on the association between APAs and IUFD have usually 
analyzed the prevalence of APAs in blood samples collected within months after suffering IUFD.
To our knowledge, the prevalence of APAs several years after the incident, among women with a 
history of IUFD, has not been reported.
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2.     Background
2.1   Stillbirth - intrauterine fetal death (IUFD)
2.1.1   Definition
Inconsistent use of definitions and terminology has contributed to confusion about stillbirths or 
IUFDs (I will use the fraises/terms interchangeably in the thesis). In addition to changes in 
definitions over time, there are great variations in the terminology between countries, with 
greater variability between high-income countries than between low-income countries [9,10]
(Figure 2.1). In USA alone nine different definitions have been reported [11]. The gestational 
age by which stillbirth is defined varies from 18 to 28 weeks [12]. The WHO definition of 
stillbirth refers to the birth of an infant weighing at least 500 g, or born at 22 or more completed 
weeks’ of gestation, or with a crown-to-heel length of 25 cm or more [13]. In this definition birth 
weight takes priority over gestational age since birth weight is thought to be more reliably 
reported, even though in low-income countries many stillborn infants are never weighed [14,15].
However, in many instances the use of the gestational age is preferred rather than birthweight, 
especially in high-income countries where ultrasound timing of pregnancy is standard practice. 
This leads to higher reported stillbirth rates; as an example, if gestational age (> 22 weeks) is 
used rather than birthweight (> 500 g) in Norway, the reported stillbirth rate is 15% higher [16].
For international comparison, WHO recommends reporting stillbirths in the third trimester, 
meaning stillbirths of infants weighing 1000 g or more, born at 28 or more completed weeks’ of 
gestation, or with a crown-to-heel length of 35 cm or more [13,17]. Perinatal mortality is a wider 
term and includes neonatal deaths in the first week of life in addition to stillbirths. Neonatal 
mortality refers to the death of a live born infant within the first 28 days of life (Figure 2.1).
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Figure 2.1. Terminology. modified from Lawn JE et al. 2011 [18] with permission.
2.1.2     Incidence                    
Counting the numbers and registering causes of stillbirths is essential in any approach to 
prevention. Stillbirth is not a rare incident and each day more than 7300 babies are stillborn on a 
worldwide basis (www.thelancet.com/series/stillbirth (from the executive summary for the 
series)). If stillbirths were aligned with the leading global causes of death in all categories, they 
would rank fifth among the global health burdens [19,20]. In 2009, the worldwide estimated
third trimester stillbirth rate was 18.9 stillbirths per 1000 births, declining from 22.1 per 1000 
births in 1995 [21]. The highest estimated rate of 47 per 1000 births was in Pakistan and the 
lowest in Finland (2.0 per 1000 births). In 2008 all the Nordic countries had third trimester 
stillbirth rates in the range 2.0-2.7 per 1000 births [21]. The incidence of IUFD in developed 
countries varies from approximately 2 – 7.5 per 1000 pregnancies [14,21-23]. Currently
stillbirths account for more than 50% of all perinatal deaths in developed countries [22,24]. For 
comparison, stillbirths are 10 times more common than the sudden infant death syndrome (SIDS)
[25].
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The estimated number of global third trimester stillbirths (> 28 weeks) was 2.64 million
(uncertainty range 2.14 - 3.82 million) in 2009, 76.2% occurring in South Asia and Sub-Saharan 
Africa [14,21]. These are the estimated numbers, but probably another 1 – 2 million stillbirths 
occur, that are not reported [26]. Stillbirths occurring before 28 gestational weeks are rarely 
reported in low-income countries [16], and many other countries do not estimate their numbers,
even though these can represent one third of all stillbirths in high-income countries [27]. Of all 
stillbirths, 98% occur in low- or middle-income countries, and low-income countries are now 
where high income countries were 50-100 years ago in terms of stillbirth rates [9,28]. In high-
income countries, some ethnic and lower income groups have higher stillbirth rates than the 
national average [18]. Such variations in stillbirth rates within the same country are reported to 
be closely associated with social deprivation, poor maternal health and availability and quality of 
health services [29] and are probably a sensitive marker of inequity [30]. The overwhelming 
preponderance of stillbirths in low- and middle-income countries can be explained by poor
obstetric care as well as higher prevalence of risk factors, especially nutritional factors and birth 
spacing [31]. Intrapartum stillbirths, viable with better obstetric/intrapartum care [32], account 
for almost half of all stillbirths [18] in low-income countries, but only rarely occur in developed 
countries (less than 0.5 per 1000 total births) [18]. Intrapartum stillbirth rates have been proposed 
as a measure of quality of intrapartum care [33].
In high-income countries approximately 5 per thousand pregnancies, that reach 22 
gestational weeks, result in stillbirth [34], or if using the international comparison limit of 28 
gestational weeks, almost four per 1000 of all births [21]. The rate of perinatal deaths has 
declined markedly over the past 50-60 years [35], to a large extent on account of changes in 
obstetrical practice and antenatal care. Several strategies have contributed to this. Firstly,
elimination of risk factors with better control of diabetes and hypertensive disorders and 
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reduction in maternal smoking. Secondly, prevention of stillbirth by antenatal monitoring with 
non-stress tests, biological profile or Doppler examinations and correct timing of induction of 
labor. Thirdly, intrapartum monitoring and finally, antepartum screening for fetal anomalies [36].
However, while neonatal deaths have been steadily decreasing the last 20-30 years, the stillbirth
rates have been relatively stable [9]. It seems that there has been some reduction in late (>28
weeks), but hardly in early stillbirths [27,37]. There are even reports of  increased incidence of 
stillbirths the last decade [25].
2.1.3     Causes
Targeting specific causes and specific clinical scenarios is crucial for further prevention of 
stillbirths in high-income countries. However, the determination of a cause can be challenging, 
since the circumstances of the death can be complex and thus the value of a thorough 
investigation must be emphasized. The most common causes of stillbirth worldwide are: 
complications of childbirth, maternal infections in pregnancy, maternal disorders, fetal growth 
restriction and congenital abnormalities [18]. Causes as well as risk factors differ between low-
and high-income countries [38] and these differences correlate with the stillbirth rates [18]. As 
an example the proportion of intrapartum stillbirths is higher in countries with higher stillbirth
rates. But the causes differ not only because of their true prevalence, but also because of different 
potentialities in identifying the causes [16].
Causes of stillbirths include congenital anomalies, infections, asphyxia, placental 
abruption and umbilical cord accidents. In developed countries 25% of stillbirths have an 
intrinsic fetal cause, 6-12% are caused by or associated with a major chromosomal abnormality 
and a number of autosomal recessive metabolic disorders are known to result in stillbirth [39].
Maternal and/or fetal infections probably cause 10-25% of stillbirths, most often in the early 
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preterm period (<28 weeks of pregnancy) [40,41]. The most important infectious agents reported 
in high-income settings are parvovirus B19, group B streptococci, toxoplasma gondii, Listeria 
species, E. coli, enteroviruses, cytomegalovirus (CMV), and influenza virus [42]. Some 
pathogens like parvovirus B19, CMV and toxoplasma have a clear causal relationship with 
IUFD, while others are associated with an increased risk of stillbirth, with strong evidence of a 
causal relationship absent (colonisation with ureaplasma urealyticum, mycoplasma and group B 
streptococci) [38,40,41].
Umbilical cord accidents may cause 15% of stillbirths [43], but cord incidents are also
common in live births, so this diagnosis should be made with caution. Placental abruption
accounts for 10 – 20% of all intrauterine fetal death, but occurs in only 1% of pregnancies [44].
Feto-maternal hemorrhage (other than placental abruption) is probably underestimated as a cause 
of stillbirth, but may contribute to 5% of stillbirths [45]. About 10% of fetal deaths can be related 
to maternal medical illnesses such as hypertension, diabetes mellitus, systemic lupus 
erythematosus, chronic renal disease, thyroid disorders and cholestasis in pregnancy [46], but 
stillbirths caused by these disorders have been greatly reduced in numbers the last decades 
thanks to better management and care.  
Causes of stillbirths vary according to gestational age. Fretts et al. reported that the most 
common causes in weeks 24-27 were infections (19%), placental abruption (14%) and fetal 
anomalies (14%), with 21% unexplained, while after 28 gestational weeks unexplained stillbirth 
was the largest group (26-40%), with fetal malnutrition (14-19%) and placental abruption (12-
18%) being frequent as well [23,47]. The prevention of early fetal losses has been the most 
difficult to achieve.
2.1.3.1   Unexplained stillbirth
Unexplained stillbirth is a death unexplained by fetal, placental, maternal or obstetric factors. 
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“Unexplained stillbirth” is not synonymous with “stillbirths of unknown cause”, since the cause 
can be unknown because of lack of information or suboptimal examination and/or classification. 
Approximately 25% of stillbirths are reported to be unexplained [1,48], with numbers ranging 
from 9 – 71% [49-51]. The proportion of unexplained stillbirths varies according to the 
classification system used. Classification according to the Wigglesworth and Aberdeen 
classifications result in a large proportion of unexplained stillbirths [52,53], and such 
classification systems do not seem to adequately fulfill their purpose. The proportion of unknown 
or unexplained stillbirths is also dependent on what information is available and is higher when 
information is scarce. The last decades, the overall rate of unexplained stillbirths has declined by 
approximately 65%, but the proportion of unexplained stillbirths among all stillbirths has 
remained relatively constant, or has even increased [54-56].
The proportion of unexplained stillbirths increases with advanced gestational age, with 
half of them occurring after 38 gestational weeks [1,47,55,57], more pronounced in women of 
advanced maternal age [54]. Huang et al. described risk factors in a large study of unexplained 
stillbirth. These included: advanced maternal age, low education, small-for-gestational-age 
(SGA), large infants, primiparity, parity > 3, and the presence of cord loops [55]. Frøen et al. 
reported similar findings in Norway for sudden intrauterine unexplained death (SIUD), and pre-
pregnancy obesity and body mass index (BMI) > 25 kg/m2 in addition [1]. Smoking is also a 
well-known risk factor for unexplained stillbirth of growth restricted infants [48,58].
2.1.4     Classification of IUFD
Classification of stillbirths is needed for the purpose of prevention, counseling, quality
improvement, comparison, surveillance of health care and research both nationally and 
internationally. It should help clinicians to understand what went wrong to derive learning points 
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for best clinical practice. However, assigning a single cause of death can be challenging due to 
the complexity of the clinical situation within which the fetus dies [59]. The purpose of 
classification systems is information management: capture, storage and retrieval [60]. Therefore, 
ideally classification systems for stillbirths should be able to capture clinical entities, besides the 
direct cause of death, since this can be important for a deeper insight into the case and for 
management and counselling. The use of suboptimal classification systems may lead to loss of 
important information and contribute to a higher proportion of unexplained deaths. 
Classification of IUFDs is complex as a result of the interaction between 
pathophysiological processes in the mother, fetus and placenta. Different definitions, different 
routines in investigating and different methods of classifying stillbirths impede comparison of
causes and risk factors. Stillbirths can be classified in many dimensions: 1) gestational age at 
birth; early stillbirths (20-28 weeks) and late stillbirths (after 28 weeks) [38], 2) according to the 
onset of labor; before (antepartum) or after (intrapartum) the onset of labor, and 3) cause, which 
can be identified from different points of view: pathophysiological pathways, maternal 
conditions, obstetrical complications, fetal conditions or mechanism of death.  
Categorizing stillbirths by cause is important for targeting preventive strategies. On a 
worldwide basis this is difficult, because of limited stillbirth data in low-income countries and 
the lack of classification systems compatible for use in these countries. A good classification 
system should be useful in all countries and for all populations. Good stillbirth data are available 
in some high-income countries through national perinatal surveillance systems, although even 
within Europe there can be paucity of comparable stillbirth data [61].
Since 1954 more than 30 different classification systems have been in use [62], but
multiple classification systems with poor comparability impede international comparison of the 
causes of IUFD. A single system universally accepted would make classification easier and 
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facilitate international comparison. However, such a system does not exist, apart from the 
International Classification of Diseases (ICD) 10, which is not adapted specifically to stillbirths 
and does not fully recognize the stillborn infant [16]. The extended Wigglesworth [52] and 
modified Aberdeen [63] have been the most widely used classification systems throughout the 
world [53]. Classification systems are made with different purposes and different perspectives/ 
emphasis, but each will provide the results it was designed for. Following are some examples of 
the various approaches and classification systems for stillbirth classification: 
1) An obstetric approach in clinico-pathological classifications (developed by 
obstetricians), tries to identify why the infant died, analyzing the obstetric factors that lie behind 
the death, in addition to congenital anomaly, isoimmunization, maternal disorders and special 
fetal conditions. Here under are; a) the first approach to classification of perinatal deaths by 
Baird et al, called the Aberdeen classification [64], b) the modified version of the Aberdeen 
classification by Cole et al. [63] and c) the Whitfield classification, which is based on the other 
two, including more detailed information [65].
2) Systems based on the pathophysiological entity initiating the chain of events that leads 
to death; a) the Tulip classification based on clinical and pathological findings for the purpose of 
counseling and prevention (includes also information on the mechanism of death) [62], b) 
Perinatal Society of Australia and New Zealand – Perinatal Death Classification (PSANZ-PDC) 
[66] and c) the Causes Of Death and Associated Conditions (CODAC) classification for perinatal 
deaths [60].
3) Systems concentrating on the mechanisms of death; the Tulip classification [62].
4) Systems concentrating on fetal factors or the clinico-pathological processes within the 
infant; a) a classification based on autopsy findings by Bound et al. [67], b) a simpler 
classification, based on externally observable features, ascertained by the history – the 
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Wigglesworth classification [59], and c) a more detailed classification by Hey et al. based on the
original one by Bound et al. [68].
5) Classification of stillbirth by relevant condition at death (ReCoDe) [50]. A system that 
seeks to identify the relevant condition at the time of death in utero, in the mother, fetus or 
placenta. It seeks to establish what went wrong, either the cause of death and/or other relevant 
conditions, not necessarily why. More than one category can be coded.
6) Systems capturing associated conditions and risk factors in addition to the cause of 
death; a) PSANZ-PDC [66] and b) CODAC [60].
Some classifications include clinical conditions like hypertensive disorders and 
intrauterine growth restriction (IUGR) as causal groups [50,63,65,66], in contrast to others that 
claim that these clinical factors are manifestations, symptoms, of a pathophysiological entity, and 
should rather be recorded as associated conditions, or as risk factors, as in CODAC. Many 
systems have a hierarchical structure, one cause “winning” over another in a systematic way 
[50,59,63].  This however forces one to choose or designate only one cause for each case, 
possibly loosing important information on contributing factors. 
Simple systems deficient in subgroups can be too crude and valuable information may be 
lost [69]. Early classification systems, like the Wigglesworth [59], and Aberdeen classifications 
[64] included only few basic groups, and although newer modified versions [52,63] include 
possibilities for a more detailed classification they are still quite simple. Some newer 
classifications have attempted to obtain more information but are often mainly designed for 
countries were thorough investigation including laboratory analyses, autopsy of the infant and 
pathological examination of the placenta is possible [62] and are impractical when data is scarce 
and the only information available often through verbal autopsy (interview with the mother or 
caregiver) occurring a year or later after the loss. 
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The explained proportion of stillbirths varies according to which classification system is 
used and with the level of investigation [51,70,71]. Information on maternal and fetal health, the 
placenta and autopsy are the most important sources of information [51]. Many maternal 
conditions and characteristics are potentially associated with stillbirths, indicating the importance 
of collecting data on maternal conditions as well. Several reports have indicated the importance 
of placental pathology as a source of information in investigating the causes of stillbirths 
[51,53,72], but only the Tulip [62] and CODAC [60] classification systems include detailed 
categories for this purpose. 
2.1.4.1   CODAC classification of perinatal deaths 
The CODAC classification system is designed to retain information on the main cause of death 
as well as up to two associated conditions [60]. It is a classification system for perinatal deaths, 
recently developed by an international group of investigators. It was developed with a basis in 
some fundamental elements classification systems should incorporate [60]:
1) Compatibility with the ICD.
2) Expandability of classifications. Expandable main categories, when detailed information 
is available, but possible to use the main groups when information is limited. 
3) Capture of intrapartum events.
4) Capture of placental conditions.
5) Ability to differentiate unknown and unexplained events. 
CODAC has been evaluated and compared with 5 other classification systems [51] and 
received the highest score regarding the ability to retain important information and the ease of 
use, lowest proportion of unexplained stillbirths and a fair inter-observer agreement.  
The main focus of CODAC is the “cause of death” (COD), with the possibility of coding 
for up to two additional “associated conditions” (ACs) to preserve more detailed information
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Table 2.1. The CODAC classification system. Cause of death (COD).
CODAC – COD
Main groups
Level I
CODAC – COD
Subgroups
Level II
0: always unspecified or other
CODAC - COD
Level III
Sub-sub groups
0: always unspecified
9: always other (free text)
0 Infection 1 HIV
2 Malaria
5 GBS
6 Common bacteria of  maternal flora – non-GBS
7 Bacteria – other
9 Viral - other
Example:
The 3-digit COD 71?
Level I: 7 - Maternal
Level II: 1 - Hypertensive
                     Disorders
Level III:
0 Unspecified
1 Eclampsia
2 HELLP syndrome with or 
without eclampsia
3 Hypertension / Hypertensive 
crisis - unspecified
4 Hypertension / hypertensive 
crisis in pregnancy-induced HT/ 
Preeclampsia
5 Hypertension / hypertensive 
crisis in pre-existing HT
6 Ehler-Danlos syndrome
7 Pulmonary hypertension - other
9 Other
1 Neonatal
2 Intrapartum 1 Uterine rupture
2 Cord and placenta complications
5 Prolonged/ obstructed and incomplete labor
6 Extreme prematurity
9 Unknown (fetal respiratory failure/ asphyxia)
3 Congenital 
anomaly
1 Central nervous system
2  Cardiovascular and lymphatic vessels
7 Trisomies
4 Fetal 2 Brain injury
2 Cardiac
3 Alloimmunization
7 Hydrops of unknown origin
9 Infection / inflammation of the fetus
5 Cord 1 Knots
2 Loops
3 Abnormal insertion 
4 Focal anomaly
5 Generalized anomaly
6 Other mechanical compromise
7 Thrombosis of the cord
9 Infection / Inflammation of the cord/ vessels
6 Placenta 1 Abnormal implantation, migration or shape
2 Villous / vascular maldevelopement
3 Abruption or retroplacental hematoma
4 Infarctions and thrombi
5 Circulatory disorder
7 Transfusion and feto-maternal hemorrhage
8 Small for gestation placenta
9 Infection / inflammation of the placenta/ membranes
7 Maternal 1 Hypertensive disorder
3 Diabetes
5 Hematology
8 Trauma
9 Infection
8 Unknown 1 Unknown with no placental PAD nor autopsy
2 Unknown with no placental PAD
3 Unknown with no autopsy
5 Unknown despite autopsy and placental PAD
6 Unexplained despite full evaluation
9 Termination
The table contains the groups possible for the main (single) or secondary COD: all Level I groups (10), the Level II groups of
relevance to our study (44 of 94) and column 4 comprises an example of a 3-digit COD with the possible Level III categories  (9 
of 577).
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about the case. By this it is possible to capture the narrative of the case within the system. For 
classification in the main groups, a skilled birth attendant can easily observe the information/ 
details needed, thus the system is applicable also in low-resource settings.
For each case, CODAC allows up to three codes with three digits each (123 123 123), 
although only one code (123) is necessary. The first (or single) code represents the main COD. 
The second code can represent a secondary COD (if the first is not thought to be sufficient to 
fulfill the criteria of a solitary COD) or an AC, and the third code represents an AC. The first 
digit in each code represents “Level I” or the main categories of the COD or the AC (Tables 2.1 
and 2.2).  The second and third digits, in each code, represent Levels II and III, each level
Table 2.2. The CODAC classification system. Associated conditions (AC). 
CODAC – AC
Main groups
Level I
CODAC – AC
Subgroups
Level II
Groups 0-7: same subgroups as for COD
CODAC – AC
Sub-subgroups
Level III
0: always unspecified
9: always other
0 Infection
1 Neonatal
2 Intrapartum
3 Congenital anomaly
4 Fetal
5 Cord
6 Placenta
7 Maternal
8 Associated perinatal 0 Other or unspecified
1 Small for gestational age
2 Macrosomia
3 Multiples
4 Amniotic fluid
5 Assisted reproductive technique
6 PPROM
7 Post-term pregnancy
8 Vaginal hemorrhage
9 Sub-optimal care
Example:
The 3-digit AC 87?
Level I:  8 -Associated Perinatal
Level:II:  7 - Post-term pregnancy
Level III:
0 Unspecified
1 > 41 completed weeks
2 > 42 completed weeks
3 > 43 completed weeks
9 Other
9 Associated maternal 0 Other or unspecified
1 Obstetric history
2 Smoking
3 Recreational and addictive drugs
4 Medication – adverse effects
5 Poverty
6 Maternal characteristics
The table contains the groups possible for an AC: all Level I groups (10), the Level II groups of main groups 8 and 9 
(17 of 94) and column 4 comprises an example of a 3-digit AC with possible level III categories (5 of 577).
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representing more detailed information. Each Level I category is comprised of several Level II 
categories which in turn are comprised of several Level III categories. Stillbirth caused by 
placental abruption could have a main (or single) COD 630 (Level I - placenta, Level II-
abruption or retroplacental hematoma, Level III – unspecified), but if the cause was placenta 
infarctions the COD would be 640 (Table 2.1). To be a COD the condition should be expected to 
be mortal in a significant proportion of cases (5%) and to be an AC the condition should 
contribute significantly in explaining the circumstances of death. An AC can never fulfill the 
criteria of a COD. The system includes ten main groups (Level I), 94 sub-groups (Level II) and 
577 sub-sub-groups (Level III). 
The order of codes, both COD and AC, should preserve the relative significance and 
sequence of events, the most relevant code first. Hierarchy is only used when information on 
sequence and significance is lacking. The decision of which COD or ACs are assigned in each 
case is a subjective expert opinion, after review of all available information. For support ten 
coding rules have been defined [60] and for consistency in coding these rules need to be 
followed.
Each case is thus necessarily represented by at least one 3-digit code, but can be 
represented by as much as a three 3-digit codes.  This enables reporting for each case by groups 
of disorders rather than attributing the death to a single event or disorder. In this way CODAC is  
well equipped to capture and retain information, as was demonstrated in an assessment by the 
International Stillbirth Alliance [51]. In order to classify the case in CODAC only minimum of 
information is mandatory, but a thorough investigation and more detailed information allows 
more accurate classification. This wide frame makes CODAC suitable in different settings.
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2.1.5     Risk factors 
Definition
A risk factor is a maternal characteristic associated with and increasing the likelihood of
stillbirth, but without a known causal pathway leading to death and can be present in many cases 
of live births as well [36].
Fortunately the majority of pregnant women are at low-risk and for them the risk of a late 
stillbirth is relatively low (1-2 per 1000 pregnancies) [73]. However, identification of risk factors 
is essential for the purpose of better care and preventive measures to decrease the likelihood of 
stillbirth. This is the purpose of good antenatal follow-up and obstetrical practice. Changes in 
obstetrical practice, like the improved management of diabetes, pre-eclampsia and Rhesus-
isoimmunisation, are probably responsible for the declining stillbirth rates the last decades [73].
2.1.5.1 Sociodemographic risk factors
Maternal age 
Large epidemiologic studies have reported advanced maternal age to be associated with 
increased risk of stillbirth, not explained by age-related risk for pregnancy related complications 
such as pre-eclampsia, gestational diabetes, multiple pregnancy or placental abruption [1,23,74-
77]. The reported ORs for the risk of IUFD associated with advanced maternal age are in the 
range 1.3-1.9 for age 35-39 years and 1.7-3.3 for age over 40 years. Frøen et al. reported an OR 
of 5.1 (95% CI 1.3-19.6) for the risk of unexplained intrauterine death among women 35 years 
and older [1]. This maternal age-related risk of stillbirth has been described to increase with 
advanced gestational age and is specially associated with unexplained stillbirth [54,75,76,78].
The maternal age-related risk of stillbirth is quite important since the obstetrical population is 
changing in developed countries and the number of births to women 35 years and older is 
increasing. Interestingly Fretts et al. found that the relative risk of stillbirth for women of 
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advanced maternal age (> 35 years) had increased since the 1960’s [75]. An association between 
young age and stillbirth has also been reported, although an inconsistent finding. Bateman et al. 
found women < 19 years being more likely to have a pregnancy outcome of stillbirth, compared 
to women 20-34 years old, with OR 1.11 (95% CI 1.08-1.14) [76]. Olausson et al. investigated 
the association of young maternal age and perinatal death. The rates of stillbirth > 28 weeks 
increased gradually with lower maternal age, although not statistically significant when 
comparing women at ages < 19 years to women 20-24 years of age [79], but low maternal age 
was significantly associated with neonatal death.
Maternal weight / BMI
Pre-pregnancy obesity or increased BMI is associated with an increased risk of stillbirth [80-83],
with ORs from individual studies in the range 1.9-2.7 for overweight (BMI 25-29.9 kg/m2), and 
2.1-2.8 for obese women (BMI >30) [23]. A recent meta-analysis found the odds of stillbirth to 
be increased 23% (OR 1.23; 95% CI 1.09-1.38) and 63% (OR 1.63, 95% CI 1.35-1.95) for 
overweight and obese women, respectively [34]. This poses a growing problem since the 
prevalence of overweight and obesity is increasing in most high-income countries. In USA 54%
of women aged 20-39 are either overweight or obese [84] and Europe seems to follow a similar 
pattern albeit with some delay [85]. In fact overweight and obesity are reported to be the most 
prevalent risk factors for stillbirth in high-income countries [34]. This association appears to be 
strongest among nulliparous women [82] and seems to increase with advanced gestational age 
[81].
The risk of stillbirth associated with overweight or obesity can be mediated through other 
factors as these women have increased risk for pregnancy complications such as gestational 
diabetes and pre-eclampsia and they are also more likely to smoke and to have a low socio-
economic status [86-88]. However, overweight/obesity remains as an independent risk factor 
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even after adjusting for other known risk factors [81]. It is possible that obese women without 
clinical disease may present with metabolic and vascular abnormalities similar to those seen in 
pre-eclamptic women with failure of normal placentation [87,88]. A large Danish cohort study 
reported increased risk for stillbirth among obese women, gradually increasing with advancing
gestational age with a 340% risk after 40 weeks. They showed a similar trend among overweight 
women with doubled risk after 40 weeks. The overweight or obese women had more often 
obesity associated diseases such as hypertensive disorders and diabetes mellitus, but excluding 
those women from analysis only moderately affected the risk of stillbirth. The stillbirths among 
the obese women (without obesity related diseases) were more likely to be caused by placental 
dysfunction or to be unexplained [89].
Parity
Both primiparity [77] and multiparity [75] have been found to be associated with stillbirth [55],
but these are not consistent findings [75,90,91]. The recently published meta-analysis of Flenady 
et al. found a 42% increase in the odds of stillbirth associated with primiparity (OR 1.42; 95% CI 
1.33-1.51) [34]. The number of primiparous women of advanced maternal age (>35 years) is 
rising in high-income countries because of delayed childbearing and studies have demonstrated 
that this sub-group of older primiparous women has a greater risk of stillbirth than young 
primiparous women [81].
Socio-economic factors
Low socio-economic status has been associated with increased risk of stillbirth [34,55,92].
Socioeconomic status can be measured by several factors like: education, employment, income 
and marital status. Several studies have found single civil status to be associated with stillbirth, 
probably as a factor of lower socio-economic status as a single mother [48,49,75,78,90]. In the 
Nordic countries an association between social differences and stillbirth is reported, with a 
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relative risk in the range 1.4-1.9 for the groups with greatest deprivation [93]. Reports from other 
western countries show similar figures [94]. Smoking is probably a great contributor to stillbirths 
in some disadvantaged populations [34], and these women also have increased prevalence of 
other risk factors for stillbirth, like overweight. However, the increased stillbirth risk cannot 
entirely be explained by that, as adjusting for overweight, smoking and several other risk factors 
only slightly changes the risk estimates [92]. It has been suggested that the elevated stillbirth risk
among these women might be caused by subtle differences in care [24].
Suboptimal care
In high-income countries suboptimal care can include: delayed diagnosis of relevant pregnancy 
complications or delayed or inadequate reactions of health care providers. The pregnant women 
contribute by factors like inadequate antenatal attendance and smoking. Suboptimal care is 
reported to affect the stillbirth risk, and is shown to be associated with 10-60% of stillbirths and 
neonatal deaths in high-income countries [27]. One study found that not attending antenatal care 
was associated with a three-fold increase in the odds of stillbirth [95]. The difference in stillbirth 
risk between indigenous and non-indigenous women in Australia might also partly be explained 
by a larger proportion of indigenous women living in rural areas of socioeconomic deprivation 
with limited access to antenatal care [96]. In the USA black women have been found to be four 
times more likely to have no prenatal care and this combination of no prenatal care and black 
race has been associated with a seven-fold risk of stillbirth [95,97].
Ethnic origin
Racial disparity of stillbirth risk has been reported in several studies [76,90,91,98]. The stillbirth 
rate among non-Hispanic black women is reported to be more than double the rate of non-
Hispanic white women in USA [98], and indigenous Australian women have almost twice the 
risk of non-indigenous women [96]. Sharma et al. also found greater risk of recurrence of 
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stillbirth among African American women compared to white women, OR 2,6 (95% CI 1.2 - 5.7)
[91]. Herschel et al. found that black women had a nine-fold increase in hypertensive associated 
fetal mortality, two-fold increase in abruption and a larger proportion of deaths associated with 
SGA [99].
The higher rate of stillbirth among non-majority women has been reported even in 
countries where there is generally good access to medical care [100]. In Norway one group found 
women of non-Western origin to have increased risk for stillbirth, compared to women of 
Western origin (Western Europe except Turkey, North-America, Australia and Oceania) with an 
OR 2.2 (95% CI 1.3-3.8) [101]. The non-Western women more often neglected antenatal care 
and disregarded the advice of health-care workers, and inadequate communication was reported 
in 47% of the cases. They were also at greater risk of suboptimal care during delivery. Another 
author reported similar findings in USA with reduced prenatal-care utilization among black 
women [95]. Late attendance for antenatal care has been reported to explain some of the 
disparity in stillbirth rates in high-income countries [102].
Smoking
There is a well documented association between smoking and fetal death, with increasing risk 
with increased amount of smoking and placental pathology as a proposed pathway 
[24,78,80,103]. The OR for the association of smoking and stillbirth is reported to be in the range 
1.7-3.0 [23]. Smoking is a well known risk factor for placental abruption [104,105] and the 
higher rates of stillbirths among smokers appear mainly to be due to placental abruption and 
placenta previa [106]. There has also been reported a dose-related association between smokeless 
tobacco use and stillbirth [107], and studies from India have found an association between the 
use of biomass fuels for cooking and stillbirth [108].
A biological hypothesis regarding a causal relationship between smoking and stillbirth
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has been proposed. Smoking increases the concentration of fetal carboxy-hemoglobin in addition 
to increasing the vascular resistance by the vasoconstrictive effect of nicotine and the reduced 
prostacyclin synthesis [109-111] probably contributing to placental pathology among smokers.
Alcohol and recreational drugs
Alcohol consumption has been associated with stillbirth [112], although this is not a consistent 
finding [80]. Cocaine use has been shown, in a meta-analysis, to increase the risk for stillbirth 
six-fold, probably due to an association with intrauterine growth restriction (IUGR) and placental 
abruption [113].
2.1.5.2   Clinical risk factors
Gestational age
Figure 2.2. Gestational age, terminology.
Live births peak at term whereas IUFDs occur with decreasing frequency from the 20th 
gestational week. The majority of stillbirths occur in the preterm period, that is, before 37 
gestational weeks. Copper et al. reported in their material (USA) 51% of stillbirths occurring 
before week 28, 18% at term (37-41), and only 1% at 42 weeks or later [90]. Yudkin et al. 
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studied unexplained stillbirths after 28 gestational weeks and reported  that over half of all 
stillbirths occurred before 37 weeks’ gestation [57]. They reported the highest stillbirth rates
(stillbirths per 1000 births) in the very preterm period (< 34 gestational weeks), the lowest at 39-
40 gestational weeks’ gestation, rising at 41 weeks and later. But paradoxically, although the
stillbirth rates were highest early, the risk of stillbirth increased with advanced gestational age, 
peaking at 41 to 42 weeks. They observed this using a more appropriate method of calculating 
stillbirth risk related to gestational age. Rates are generally accepted when measuring risks. 
Stillbirth rates represent the proportion of stillbirths of total births. However, the population at 
risk for IUFD is not the population of delivered infants, but the population of unborn infants. 
Stillbirth risk is therefore better measured by the number of stillbirths divided by the number of 
unborn fetuses [57]. This is calculated by dividing the number of stillbirths at a given gestational 
week with the number of ongoing pregnancies at the same week [114]. By this measure reports 
show that even though the minority of stillbirths occur post-term (>42 weeks) the risk is 
relatively high because few pregnancies are still ongoing at such late gestational age [57,114].
Yudkin et al. showed in this way that the risk of stillbirth increased with maturity and was, for 
unexplained stillbirth after 28 gestational weeks, three times greater at 40 weeks than at earlier 
gestational ages [57]. Another study found the relative risk for antepartum stillbirth at 41 weeks 
to be 1.7 (95% CI 1.4-2.1) compared with the risk at 39 weeks [114]. The stillbirth risk in week 
41 and 42 has been reported to be two- to ten-fold the risk in week 39 and 40 [57,114,115], but 
the results regarding the association of gestational age and stillbirth have not always been 
consistent. Huang et al. found, for unexplained stillbirth of fetuses weighing more than 500g, a 
gradually increasing risk of stillbirth from week 35 onward, but the risk at or after 41 weeks, was 
not significantly increased compared with the risk at 39-40 weeks [55]. Another study showed 
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similar findings, with a trend of progressively rising stillbirth risk with advanced gestational age, 
but the significance was not calculated [78].
Multiple pregnancies
Multiple pregnancies pose an increased risk of all common pregnancy related complications, 
especially IUGR and preterm deliveries, in addition to complications specific to multiple 
pregnancies as twin to twin transfusion syndrome [116]. The risk of IUFD in twin pregnancies
has been found to be four-fold the risk in singleton pregnancies [117], with reported risk 
estimates in the range 3.2-6.2 [49,75,76]. Multiple pregnancies constitute about 3% of births, but 
about 10% of stillbirths [36]. Higher order multiples have an even greater risk of perinatal death 
[118]. Lately multiple pregnancies have become more prevalent because of assisted reproduction 
techniques and higher maternal age, and will possibly gain more importance as a risk factor for 
stillbirth [119].
Premature labor 
Risk factors associated with preterm delivery are strong predictors of stillbirth since most 
stillbirths occur in the preterm period [90]. The most common causes of stillbirths between 24 
and 27 weeks of gestation, reported from a Canadian material, were infection, placental 
abruption and lethal anomalies [47].
Placenta mediated pregnancy complications (PMPC)
Stillbirth, placental abruption, IUGR, and hypertensive disorders are denoted as the “placenta
mediated pregnancy complications”. They are thought to share the same pathogenesis of 
placental origin in many instances and tend to be associated with one another and share the same 
risk factors. The non-pregnant uterus has a high resistance circulation, but during the first half of 
a normal pregnancy, trophoblasts invade the spiral arteries changing the uterine circulation 
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dramatically, reducing the resistance [120]. Placental insufficiency probably originates/develops 
in very early pregnancy [121] and studies have suggested that complications in late pregnancy 
may be determined by impaired placental function already in the first 10 weeks after conception 
[122]. The flow in the uterine arteries can be assessed by Doppler flow velocimetry and a high 
resistance pattern of flow at the end of the second trimester is associated with an increased risk 
of IUGR and IUFD [123].
Placental abruption
Placental abruption is defined as a premature separation of a normally implanted placenta and 
complicates about 1% of all pregnancies, but accounts for 10 – 20% of all fetal deaths [34,44]. It 
has been strongly associated with stillbirth in several studies with ORs in the range 11.4-18.9 
[124,125].
The consequences of placental abruption vary from minor bleeding with little or no 
consequences, to a massive abruption leading to fetal death and severe maternal morbidity. 
Abruption involving more than 50% of the placenta is frequently associated with fetal death 
[126]. It appears that, in the vast majority of cases, abruption is the end result of a chronic 
process. Smoking, hypertension and SGA are strongly associated with placental abruption which 
indicates that problems with placentation are a common denominator for these conditions [126].
Intrauterine growth restriction (IUGR) / Small for gestational age (SGA)
IUGR is used to describe a pattern of intrauterine fetal growth that deviates from expected 
norms, whereas SGA is based on birth weight and is often defined as birth weight below the 10th
percentile for the gestational age [127]. To diagnose IUGR two ultrasound examinations, during 
the pregnancy, at least ten days apart are mandatory [127]. The two terms are not synonymous, 
as some SGA-fetuses may be constitutionally small while some normal-sized fetuses might be
originally large fetuses that are IUGR. The use of population based reference curves of 
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birthweights underestimates IUGR among preterm births, and fails to distinguish between 
constitutional and pathological smallness [128]. The accurate detection of IUGR is improved 
with customized growth charts, which take into account maternal height and weight, parity, 
ethnic origin and the baby’s gender [129].
IUGR is the condition most often associated with stillbirth (43%) and is found in the 
majority of stillbirths previously considered unexplained [46,50]. Poor fetal growth, without 
other environmental causes is assumed to indicate insufficient placental function. In a Canadian 
study the incidence of stillbirth among SGA fetuses was 46.8 per 1000, while the normal sized 
fetus had an incidence of 4.0 per 1000 (OR 11.8; 95% CI 8.1-17.1) [47]. Frøen et al. found that 
IUGR existed among 52% of all unexplained stillbirths compared to 13% of singleton liveborn 
controls  (OR 7.0; 95% CI 3.3-15.1) [48], and they also found the distribution of risk factors in 
the group with IUGR to be different from the group without IUGR. Among women with IUGR-
pregnancies smoking > 10 cigarettes, maternal overweight (BMI >25kg/m2) and low education 
were associated with unexplained stillbirth, while in pregnancies without IUGR, smoking was 
not a risk factor, but maternal age > 35 years, overweight and low education were. There appears
to be a dose-response effect, with a greater risk of stillbirth with more profound SGA [128].
Women with a previous SGA pregnancy are at increased risk of stillbirth in the 
succeeding pregnancy, particularly if the infant was delivered preterm. A Swedish study  found 
rates of stillbirths ranging from 2,4 per 1000 births among women whose first child was born at 
term and not SGA to 19 per 1000 births among women whose first child was born very preterm 
(before 32 weeks) and was SGA [130]. They found that the rate of stillbirth in the next 
pregnancy was lower for those with a previous stillbirth (7,6 per 1000 births) than for those with 
a previous SGA infant born moderately or very preterm (9,5 and 19 per 1000 births 
respectively).
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Hypertensive disorders
Hypertensive disorders (HD), comprising essential hypertension (HT), pregnancy related HT and 
preeclampsia complicate 5-10% of all pregnancies [131]. HT has been reported to have either no
[47,90] or a very modest association with stillbirth [75,76,90] and Warland et al. even reported a 
decreased risk of stillbirth among women with HT [132]. One author found chronic HT, but not 
gestational HT, to be associated with stillbirth (aOR 3.46; 95% CI 1.1-10.5) [133]. Historically 
HT has been responsible for a notable proportion of fetal deaths, but optimal management has 
considerably reduced the risk of perinatal death associated with HT [134].
Preeclampsia complicates approximately 3% of all pregnancies and can induce serious 
complications for both mother and fetus. The consequences for mother and child depend on 
gestational age at onset, severity, and timing of diagnosis. Early onset (before gestational week 
32) occurs among approximately 10% of the cases and is usually a sign of a more severe disease, 
with greater risk of complications [131]. Preeclampsia is associated with both IUGR and 
placental abruption.
Infertility
Women who choose to delay childbearing are also more likely to have a history of infertility and 
are therefore more likely to conceive with reproductive technologies. There has been 
demonstrated an association between advanced reproductive technologies and perinatal mortality 
[23,118]. The more frequent multiple gestations in these pregnancies account for a significant 
portion of the increased risk. However, an increased risk has also been demonstrated in singleton 
pregnancies after in vitro fertilization or ovarian stimulation, associated with prematurity and 
low birth weight [135,136].
A history of stillbirth
Women with a previous stillbirth have as much as 2-10 fold increased risk of a repeated stillbirth
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compared to women with no previous stillbirths [34,91,137-139]. Women with a history of 
stillbirth have an increased risk of gestational diabetes, preeclampsia and IUGR, but these factors
alone do not entirely explain the increased risk of a second stillbirth, although the risk depends 
on the etiology and gestational age of the prior stillbirth, presence of IUGR, and race [130,137].
Women with a history of other complications in previous pregnancies also have an increased risk 
of future stillbirth [130] and women with a previous stillbirth have been found to have an 
increased risk of other pregnancy complications in the subsequent pregnancy [140,141].
Heinonen et al. found that women with a history of stillbirth of other causes than maternal 
conditions or fetal abnormalities had more often placental abruption, preterm deliveries, and low-
birthweight in the subsequent pregnancy [140]. Women with a previous fetal loss in gestational 
weeks 13 – 24 have also been found to have an increased risk of stillbirth in the succeeding 
pregnancy [142].
Previous Caesarean delivery
A previous Caesarean section has been associated with an increased risk for stillbirth in a 
Scottish study (1992-1998) that demonstrated a 2-fold risk of antepartum stillbirth at 39 weeks’ 
gestation compared with a previous vaginal birth [143]. The difference was mostly due to an 
excess of unexplained stillbirths. The results were confirmed among women delivering in the 
years 1999-2001, utilizing data from the same source [144]. An analysis of birth certificate data 
from USA was not able to demonstrate a similar association, but found quite the opposite [145],
but the large study population was of an extremely heterogeneous nature. A meta-analysis of 6 
studies demonstrated a 20% increase in the odds of stillbirth associated with previous Caesarean 
section [34], although confounding due to the indications of the Caesarean sections could not be 
excluded.
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Maternal medical diseases 
Maternal medical disease can induce an increased risk of stillbirth, although better treatment in 
the last decades has reduced the risk associated with several conditions. Estimates suggest that 
maternal disease can contribute in 10% of fetal deaths [146]. Hypertension and diabetes mellitus 
(DM) are the most common medical problems complicating pregnancy and have earlier been
associated with a great proportion of IUFD. However, good antenatal management reduces the 
risk of perinatal death associated with these conditions to a level only slightly above that of the 
general population [134]. Fretts et al. found that although the rates of stillbirth associated with 
insulin-dependent DM decreased from the 1960s to the 1980s, women with DM were still at a
significantly increased risk for stillbirth in the 1980s [47]. Maternal hypertension, on the other 
hand, resulted in an increased risk of stillbirth in the 1960s, but not the 1980s [47]. Fretts 
reported, in a review article in 2005, ORs for the association with stillbirth to be 1.5-2.7 for 
chronic hypertension, 1.2-2.2 for DM treated with diet and 1.7-7.0 for insulin-dependent DM 
[23].
Other maternal medical diseases reported to be associated with stillbirths are: systemic 
lupus erythematosus (OR 6-20), renal disease (OR 2.2-30), thyroid disorders (OR 2.2-3.0), 
thrombophilia (OR 2.8-5.0), asthma, cardiovascular disease, and cholestasis of pregnancy (OR 
1.8-4.4) [23,146]. Pregnancy loss associated with maternal medical disease typically occurs in 
women with severe disease.
Diabetes mellitus
The majority of stillbirths associated with diabetes are reported to occur in the third trimester in
patients with poor glycemic control and complications of macrosomia, polyhydramnion, IUGR 
and preeclampsia [147]. It appears that DM types 1 or 2 are more often associated with stillbirth 
than gestational diabetes [81,148]. In a review article from 2007, Silver summarized the risk of 
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stillbirth associated with diabetes and found OR 2.5 for DM type 1 and 2 but no association 
between gestational diabetes and fetal death [146]. However, some studies have not 
demonstrated an association between diabetes and stillbirth at all [75,76,90] and reports from 
referral centers suggest that with optimal management the risk of perinatal death associated with 
diabetes is only marginally above that of the general population [75]. Diabetic women have 
increased rates of fetal anomalies, hypertension and obesity, but the increased risk of fetal death 
persists after controlling for these factors [146]. One study demonstrated that women with a
previous stillbirth more often had abnormal glucose tolerance and gestational diabetes in a 
subsequent pregnancy and speculated that undiagnosed gestational diabetes could possibly 
contribute to some unexplained stillbirths [141].
Maternal hemoglobin concentration
Plasma volume expansion and reduced hemoglobin concentration in the course of the pregnancy 
are normal physiologic responses to pregnancy. Both high and low hemoglobin concentrations 
have been associated with increased risk of perinatal death [149] and stillbirth [150,151].
Stephansson et al. found both low (< 11.5 g/dL) and high (> 14.6 g/dL) hemoglobin 
concentrations in early pregnancy to be associated with an increased risk of stillbirth and  a 
relatively large decrease in hemoglobin concentration during pregnancy seemed to be protective 
[151]. Elevated hemoglobin in early pregnancy and failure of significant hemodilution resulted 
in a 2-fold increase in stillbirth risk. High hemoglobin level (> 14.6 g/dL) at first antenatal visit 
was specially associated with SGA stillbirths or preterm stillbirths [151]. Frøen et al. 
demonstrated that women with hemoconcentration, with the lowest hemoglobin measured  
during the pregnancy greater than 13.0 g/dL, had a 9-fold increase in the risk of unexplained fetal 
death [150].
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2.2     Thrombophilia
Definition
Thrombophilia is a hereditary or acquired abnormality of blood coagulation that predisposes an 
individual to developing thrombosis, either venous or arterial. The hemostatic abnormalities do 
not necessarily cause thrombosis, but may weaken the ability to cope with a hypercoaguable
insult. The risk of thrombotic complications is determined by many other factors in addition to 
thrombophilia, and the presence of several risk factors simultaneously is likely to augment the 
thrombotic risk [152,153].
2.2.1     Coagulation
The coagulation cascade describes a series of reactions that ultimately lead to the generation of 
thrombin, which in turn cleaves fibrinogen. The three phases of the coagulation (cell-based 
model) are: the initiation-, amplification- and propagation phases (Figure 2.3). Cell-based 
coagulation is initiated when flowing blood, with factor (F) VII, comes in contact with cells 
expressing tissue factor (TF). TF is expressed by fibroblasts and smooth muscle cells 
surrounding the endothelium and is normally not exposed to circulating blood [154]. An injury 
of a vessel leads to the formation of a platelet clot and the exposure of TF to circulating blood
leading to activation of the coagulation. Once bound to TF, FVII is activated (FVIIa). The
activated TF/FVIIa complex activates FX and FIX. The coagulation process eventually leads to
the conversion of prothrombin to thrombin [154]. FXa remaining on the cell surface, with FVa
as a cofactor, converts prothrombin to thrombin. At first small amounts of thrombin are 
produced, which plays a key role in the amplification phase when thrombin activates platelets in 
addition to  FV, FVIII, and FXI which in turn results in greater amounts of thrombin being 
produced [154,155]. This occurs on the surface of the activated platelets.
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Figure 2.3. Cell-based model of coagulation. With permission from Vine AK, 2009 [154].
                          
             
Of most importance in the propagation phase are the tenase- and prothrombinase-
complexes, which both are assembled on the surface of activated platelets and are dependent on 
negatively charged phospholipids and calcium [155]. Activated FVIII (FVIIIa) is the co-factor of 
FIXa and together they form the tenase-complex. The tenase-complex activates FX which then 
forms the prothrombinase-complex with FVa as a cofactor [154]. The prothrombinase-complex 
cleaves prothrombin, thus producing great amounts of thrombin, which in turn converts soluble 
fibrinogen into fibrin to form a hemostatic fibrin clot, stopping the bleeding.
Simultaneously with the activation of the coagulation, anticoagulation systems are
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activated to prevent uncontrolled coagulation and thrombosis. The three most important systems 
are the TF pathway inhibitor (TFPI) system, the antithrombin (AT) system, and the protein C
(PC)/ protein S (PS) system. The TFPI-system inhibits the TF/FVIIa-complex, inhibiting the 
initiation phase [156].  AT inhibits all activated coagulation enzymes including thrombin, FIXa,
FXa and FVIIa (when bound to TF). This inhibition is greatly accelerated by heparins. PC is 
activated by thrombin in combination with an endothelial cell receptor (EPCR, endothelial PC 
receptor) and thrombomodulin. As thrombin binds to thrombomodulin it loses the ability to 
convert fibrinogen to fibrin. Activated PC (APC) in combination with PS inactivates FVa and 
FVIIIa [154,155].
2.2.2     Inherited thrombophilia
Definition
Hereditary thrombophilia is an inherited abnormality, based on a genetic mutation in the genes 
coding for either coagulation factors such as FV and prothrombin, or anticoagulants such as AT,
PC or PS. The genetic abnormalities result either in “gain of function” (coagulation factors) or 
“loss of function” (coagulation inhibitors).  
Factor V Leiden (F5 rs6025)
The Leiden variant of coagulation FV (FVLeiden) is caused by a polymorphism in the gene coding 
for FV, a substitution of adenine for guanine at nucleotide 1691 in exon 10 of the F5 gene, which 
predicts an arginin by glutamine replacement at position 506 in the mature FV molecule. This 
polymorphism causes a change in the structure of FV that has important consequences for the 
function of FV both in the coagulation and anticoagulation pathways. The APC-mediated 
inactivation of FVa is impaired, in addition to impairment of the cofactor function of FV in the 
APC-mediated inactivation of FVIIIa [157,158]. This results in a slower degradation of FVa and 
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FVIIIa and an increased risk of thrombosis. This condition is defined as APC-resistance. 95% of 
cases of APC-resistance are caused by FVLeiden [159]. Heterozygosity for the polymorphism is 
the most common heritable thrombophilia in Caucasian populations and is found in 2-15% of the 
general population, more prevalent in northern than in southern Europe [160,161]. In Norway the 
prevalence of factor V Leiden has been reported to be 7-8% [162,163]. FVLeiden is associated 
with relatively mild thrombophilia and individuals heterozygous for the polymorphism have a 
five to ten-fold increased risk for thrombosis compared to non-carriers [164]. Homozygosity 
results in a more severe thrombophilia with 50 to 100-fold increased risk of thrombosis [164].
Prothrombin gene G20210A polymorphism (F2 rs179963)
Prothrombin is a vitamin-K dependent protein which is converted by the prothrombinase 
complex to thrombin in the propagation phase of the coagulation [154]. The prothrombin gene 
G20210A polymorphism (prothrombin polymorphism) causes increased serum concentrations of 
prothrombin which leads to increased risk of thrombosis [165]. Approximately 1% of blood 
donors in Oslo, Norway have this polymorphism [162], but prevalences in the range 2-6.5% are 
reported in Europe, higher in southern than northern Europe [165,166]. Asymptomatic carriers of 
the polymorphism have a similar incidence of venous thrombosis as carriers of FVLeiden.
Antithrombin deficiency
AT deficiency is the most severe thrombophilic condition and causes a profound increase in 
thrombosis risk [167]. Several point mutations in the gene coding for AT cause either reduced 
concentrations of the protein (type I antithrombin deficiency) or reduced activity (type II) [168].
Heterozygous type I deficiency is associated with an approximately 10-fold increased risk of 
thrombosis. No case of homozygous type I deficiency has been described suggesting that 
complete AT deficiency is incompatible with life [169]. Heparin accelerates the inhibition rate of 
AT 1000-fold. A study among Canadian blood donors estimated a prevalence of 0.2% [170], but 
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prevalence of 0.02% has also been demonstrated [171]. AT levels are unchanged in normal 
pregnancy [172].
Protein C deficiency
PC is an anticoagulant protein, produced in the liver, vitamin-K dependent, activated by 
thrombin. In its activated form it mediates the inactivation of FVa and FVIIIa. Many different 
mutations can cause deficiency of the protein by either reduced activity or quantity. Deficiency 
results in reduced inactivation of FVa and FVIIIa and therefore an increased risk of thrombosis 
[173]. The prevalence was found to be 0.2% in a study of Scottish blood donors [174].
Pregnancy does not modify PC levels [175].
Protein S deficiency
PS is an anticoagulant protein, mainly derived from liver synthesis. About 60% is bound to C4b 
binding protein, but only free PS has anticoagulant properties [176]. Deficiency can be caused by 
reduced total and free PS, reduced APC cofactor activity, or normal total PS but reduced free PS
[173]. PS acts as a cofactor for APC and together they inactivate FVa and FVIIIa [154]. The 
prevalence of PS deficiency is demonstrated to be 0.03-0.13% [177]. Levels of the C4b-binding 
protein are increased in pregnancy, with the combined oral contraceptive pills and inflammation, 
leading to a reduction in the concentration of free PS. Reduced concentrations of PS associated 
with these conditions [178,179] and variations in PS levels related to age and gender can cause
misdiagnosis [180,181]. However, recent reports have demonstrated that women using second 
generation oral contraceptives have almost normal PS levels and that lowering the reference 
values results in better specificity and minimizes misclassification [182].
Other inherited thrombophilias
A number of polymorphisms of other coagulation proteins have been associated with venous
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thromboembolic disease, but these will not be discussed here.
2.2.3     Acquired thrombophilia
Definition
Acquired thrombophilia refers to a group of conditions, not congenital, that may develop 
throughout life and augment the risk of thrombosis. These include, among other conditions: 
pregnancy, cancer, surgery, infection, hypovolemia, thrombocythemia, and antiphospholipid 
antibodies (APAs) [183].
Antiphospholipid antibodies
APAs, a heterogeneous group of acquired autoimmune antibodies, are associated with acquired 
thrombophilia, relevant in the case of pregnancy complications. Of particular interest are lupus 
anticoagulant (LA), anti-2-glycoprotein 1 antibodies (anti-2-GP1) and anti-cardiolipin 
antibodies (aCL). They recognize epitopes expressed by phospholipid-binding proteins or 
protein-phospholipid complexes. They can in vitro act as coagulation inhibitors in phospholipid 
dependent coagulation assays.  The binding of antibody-antigen complexes to negatively charged 
phospholipids on the cell membrane, in vivo, induces a procoagulant state due to inhibition of 
anticoagulant reaction and cell-mediated events. 
The APAs are relevant for the Antiphospholipid Syndrome (APS), the most common 
cause of acquired thrombophilia [167]; an antibody mediated thrombotic disorder, which is 
defined by venous or arterial thrombosis and/or specific pregnancy complications in patients 
with persistently positive tests for APAs [184]. The prevalence of APAs (LA or aCL) in the 
general population, is found to be in the range 1-5% among young healthy controls [185], but 
there are discrepancies between individual studies due to assay differences, definition of cut-off 
values and referral bias.  
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2.3     Thrombophilia and IUFD
Successful outcome of pregnancy is dependent on the development of adequate placental 
circulation. This includes adequate trophoblast invasion into the uterine vasculature and the 
development and maintenance of an adequate utero-placental circulation. Abnormalities in 
placental vasculature as inadequate invasion by the trophoblast or damage to the maternal vessels 
supplying the placenta lead to impaired flow and prothrombotic changes which may result in 
pregnancy complications, such as miscarriages, preeclampsia, IUGR, placental abruption or 
IUFD denoted as  the “placenta mediated pregnancy complications” (PMPC) [186,187].
Major physiological changes of hemostasis occur during normal pregnancy; increased 
concentrations of the procoagulant factors FVIII, FV and fibrinogen, reduced anticoagulant 
activity with reduced concentrations of PS and acquired APC-resistance in addition to reduced 
fibrinolytic activity [187,188]. These adaptations are necessary for the development of an 
adequate placental circulation and to secure adequate hemostasis during delivery and the post-
partum period. When pregnancy has been established, the normal placental circulation is 
maintained by a dynamic balance between the coagulation and fibrinolytic systems. The 
backside of these adaptations is that they also induce an increased risk of thrombosis, greater 
among women with thrombophilia. 
Fetal loss in women with thrombophilia could be explained by excessive thrombosis of 
the placental vessels, placental infarction and secondary uteroplacental insufficiency [189].
However, it is unlikely that hypercoagulability with thrombosis of placental vasculature is the 
main pathophysiological pathway. Other mechanisms are probably involved, since adverse 
pregnancy outcome can occur in thrombophilic women without placental thrombosis [190].
Prevention of implantation by inadequate trophoblast invasiveness or damage to decidual or 
chorionic vessels is described for the APS [191]. Suggested mechanisms are by alteration of cell 
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surface adhesion molecules of the maternal vessel wall or trophoblasts and damage to 
trophoblasts by activation of the compliment system or a pro-inflammatory response [192].    
Kupferminc et al. reported in 1999 that 65% of women with some form of PMPC had 
positive tests for heritable or acquired thrombophilia [193]. In pregnancies with signs of 
placental insufficiency, like IUGR or placental infarction, thrombophilia is more likely to 
contribute to a fetal death [194] and the co-existence of thrombophilias appears to increase the 
risk of obstetric complications [195].  However, thrombophilia is common in normal individuals. 
Therefore one should be cautious in attributing stillbirth to thrombophilia in women who test 
positive as most of them will never experience a stillbirth. 
2.3.1     Inherited thrombophilia and IUFD
Inherited thrombophilias have been associated with an increased risk of stillbirth in the third 
trimester, although causality has not yet been reasonably documented [196,197]. The proposed 
mechanisms are by 1) microthrombosis in the placental bed, causing placental infarctions and a 
subsequent compromise of the feto-maternal circulation or 2) impeding the initial placentation 
process by increased generation of thrombin and consequently excess generation of fibrin and 
fibrin degradation products that can induce apoptosis of trophoblasts resulting in early fetal loss
or later placental insufficiency and IUFD [189,198-200]. Case series and retrospective studies 
have reported increased risk of IUFD associated with the FVLeiden polymorphism [8,193],
G20210A polymorphism of the prothrombin gene [201,202] and deficiencies of the 
anticoagulant proteins; AT, PC and PS [8,203]. However, these findings are not consistent and 
no large population based studies have been performed to evaluate these associations. The 
inconsistencies between studies may reflect small sample size, inconsistent case definition and 
differences in the definition of IUFD/stillbirth. The results of individual studies have been 
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summarized in meta-analyses. Robertson et al. [6] demonstrated an association between fetal loss 
in the third trimester and heterozygous FVLeiden (OR 2.06; 95% CI 1.1-3.86, based on 6 studies), 
heterozygous prothrombin polymorphism (OR 2.66; 95% CI 1.28-5.53, based on 5 studies), and 
PS deficiency (OR 20.09; 95% CI 3.7-109.15, based on 2 studies) [6]. The risk associated with 
AT deficiency and PC deficiency was not found statistically significant, based on 1 and 2 studies 
respectively [6]. A meta-analysis of Rey et al. from 2003 showed similar results and included 
many of the same studies [5]. They found an association of FVLeiden (OR 3.26; 95% CI 1.82-
5.83) and non-recurrent fetal loss after 19 weeks of gestation, the prothrombin polymorphism 
(OR 2.3; 95% CI 1.09- 4.87) and PS deficiency (OR 7.39; 95% CI 1.28-42.83) and non-recurrent 
fetal loss after 20 and 22 weeks of gestation respectively. Two of six studies for FVLeiden, two of 
five for prothrombin polymorphism and two of three for PS deficiency showed significant 
associations with IUFD.   
Factor V Leiden
Of interest was that none of the individual studies included in the meta-analysis of Robertson et 
al. [6], addressing the association of FVLeiden and late fetal loss, found significant associations. 
Martinelli et al. studied 67 women with unexplained fetal death at or after 20 gestational weeks 
[201], Meinardi et al. registered fetal loss after 20 gestational weeks in a cohort of 228 carriers of 
FVLeiden [204] and Rothbart et al. studied 14 women with IUFD after 24 weeks without apparent 
explanation. The study of Bare et al. registered intrauterine death among 128 FVLeiden carriers 
[205], Agorastos et al. studied eight women with stillbirth after 24 gestational weeks [206], and 
Many et al. investigated 40 women with IUFD at or after 27 weeks [202]. A population based 
study in Germany also failed to demonstrate an association between FVLeiden and stillbirth in the 
third trimester [207], as did a prospective study of Clark et al. [208], but Clark’s study only 
included 22 stillbirths at or after 24 weeks of gestation. Two studies included in the meta-
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analysis of Rey et al. found a significant association of FVLeiden and IUFD [5]. The study of Gris 
et al. of 232 women with one or more unexplained fetal loss after 22 gestational weeks
demonstrated an OR 4.8 (95% CI 1.8-12.4) for the association and Kupferminc et al. who studied 
12 women with stillbirth after 23 gestational weeks found an OR 4.9 (95% CI 1.1-22.3) [8,193].
Prothrombin gene G20210A polymorphism
The association of the prothrombin polymorphism and stillbirth appears to be more consistent 
than the association with FVLeiden. Nevertheless, of five individual studies included in the meta-
analysis of Robertson et al. the three following studies did not show significant associations: Gris 
et al. studying 232 women with one or more unexplained fetal loss after 22 gestational weeks [8],
Kupferminc et al studying 16 women with stillbirth after 23 gestational weeks [209], and Alonso 
et al. investigating 8 women with IUFD at or after 23 gestational weeks [210]. The two studies 
that found significant associations were the study of Martinelli et al. who studied 67 women with 
fetal death at or after 20 weeks of gestation with OR 3.16 (95% CI 1.02-9.75) [201] for the 
association and the study of Many et al. who found an OR of 2.3 (95% CI 1.3-4.0) among 40 
women with unexplained IUFD at or after 27 weeks of gestation [202].    
Antithrombin, Protein C and protein S deficiencies
Few studies have been able to study the association of AT, PC or PS deficiencies and IUFD, 
since the prevalence of these deficiencies is low and the sample size of individual studies is 
usually small. Preston et al. (the EPCOT-study) found that six of 108 women with AT deficiency 
compared to six of 395 women with no known inherited thrombophilias had stillbirths in the 
third trimester (> 28 weeks), OR 5.2 (95% CI 1.5-18.1) [211], but they did not find stillbirth to 
be significantly more prevalent among women with PC deficiency. The meta-analysis of Rey et 
al. was not able to analyze the association of AT or PC deficiencies and fetal loss at different 
gestational ages, but no significant associations were found with fetal loss in general [5].
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Many et al. found an association with PS in a study of 40 women with unexplained IUFD 
at or after 27 gestational weeks. Three of 40 cases and none of the 80 controls had PS deficiency 
(OR 3.2; 95% CI 2.4-4.1) [202]. Gris et al. did also find a positive association among 232 
women with one or more unexplained stillbirths after 22 gestational weeks with an OR 23.05 
(95% CI 2.96-179.62) [8].
2.3.2   Antiphospholipid antibodies and IUFD
Specific pregnancy outcomes and complications are features of the antiphospholipid syndrome, 
namely: a) one or more unexplained deaths of a morphologically normal fetus at or beyond 10th
week of gestation, with normal fetal morphology documented by ultrasound or by direct 
examination of the fetus, or b) one or more premature birth of a morphologically normal neonate 
before the 34th week of gestation because of: (i) eclampsia or severe preeclampsia defined 
according to standard definitions, or (ii) recognized features of placental insufficiency, or c) 
three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, 
with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal 
causes excluded [184].
Retrospective and prospective studies have found APAs to be associated with fetal loss
and it is documented that 15% of women with recurrent pregnancy loss have APAs [8,212,213].
An association between a circulating anticoagulant and pregnancy loss was first reported in the 
1950s [214]. In 1985 the presence of aCL was first associated with pregnancy loss and Lockshin 
suggested subsequently that aCL was a more sensitive test than LA to identify women at risk of 
pregnancy loss [215]. In 1989 a large study reported an association of LA with recurrent 
spontaneous abortion and fetal death after 10 gestational weeks [216]. The lack of concordance 
between assays for LA and aCL has indicated the importance of obtaining results from both 
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assays [217]. APAs have also been demonstrated, in prospective studies, to be associated with 
other pregnancy complications [218,219].
It appears that the association of APAs with early fetal loss is better documented than the 
association with stillbirth. Results of individual studies on the association of APAs and stillbirth 
have been inconsistent, but the sample size is often limited. One of the first reports focusing on 
late fetal loss (at or after 20 gestational weeks) was published in 1994. Bocciolone et al. studied 
99 women with unexplained fetal death at or after 20 gestational weeks and found a significant 
association between aCL (OR 21.0; 95% CI 1.21-364.5), but not LA (OR 8.06; 95% CI 0.43-
151.85) [6,7]. Comparison of individual studies has been difficult because of methodological 
differences between studies, like different selection of cases and controls, different assays, and 
different definitions of reference values. The results of studies have never the less been 
attempted summarized in meta-analyses. A meta-analysis of Robertson et al. from 2005 found an 
association between aCL, but not LA, and stillbirth in the third trimester, OR 3.3 (95% CI 1.62-
6.7), based on 6 studies and 2.38 (95% CI 0.81-6.98), based on 3 studies, respectively [6]. Three 
of the six individual studies, including the study of Bocciolone et al. (mentioned earlier), 
reporting on aCL found a significant association with late fetal loss [7,8,220]. De Carolis et al. 
studied 75 women with IUFD after 20 weeks and Gris et al. investigated 232 women with one or 
more unexplained IUFDs after 22 gestational weeks. Among the three studies that did not find a 
significant association Yasuda et al. analysed aCL in the first trimester among 860 pregnant 
women and prospectively registered fetal deaths after 24 weeks and other pregnancy 
complications. Two aCL positive and one aCL negative women experienced stillbirth [221]. In 
the study of Alfirevic et al. one of 18 women with unexplained stillbirth after 23 gestational 
weeks and three of 44 controls were aCL-positive and Infante-Rivard et al. investigated 23 
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women with fetal loss after 28 weeks, of which none were positive for aCL [221-223]. Only the 
study of Gris et al. showed a significant association between LA and stillbirth [8].
2.4     Prevention of stillbirths in high-income countries 
The interventions to prevent stillbirths fall in three main strategic areas: 1) improving the health 
and well-being of women, 2) detection and management of women at risk during pregnancy and 
3) improvement of information and standards of maternity care [27]. The cornerstone of 
prevention of intrapartum stillbirths is the management of labor and delivery. Intrapartum 
stillbirths have almost disappeared since intrapartum fetal monitoring was introduced. For the 
prevention of antepartum stillbirths optimal timing of delivery is crucial, but in order to 
accomplish that, pregnancies at risk/risk factors have to be detected. This may be achieved with 
high quality antenatal care, accessible to all women [27]. Either elimination of the risk factor, if 
possible, and/or surveillance in continued pregnancy with optimal timing of delivery will 
hopefully prevent an IUFD. However, the most common error in reducing potentially 
preventable stillbirths has been demonstrated to be failure to adequately diagnose and manage 
IUGR and to recognize maternal medical risk factors [224].
Tests of fetal well-being can potentially assist in decision making regarding timing of 
delivery. Various methods of fetal antepartum monitoring exist; fetal movement counting, non-
stress test (cardiotocogram (CTG)), stress test (contraction based CTG), biophysical profile, 
ultrasound and Doppler flow velocimetry (measures blood flow dynamics in uterine, umbilical 
and fetal arteries). In at-risk pregnancies assessment of fetal growth by ultrasound should be 
considered since antepartum surveillance with optimal timing of delivery has been demonstrated 
to improve outcomes in IUGR pregnancies [225]. The use of Doppler flow velocimetry of 
umbilical and fetal arteries in high risk pregnancies has also been demonstrated, in a meta-
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analysis, to be associated with a 29% overall reduction in perinatal mortality, although a specific 
effect on stillbirths was not significant [226]. However, no methods of fetal monitoring have 
been shown to reduce the risk of stillbirth when used for screening in unselected populations [38]
and data regarding the cost-effectiveness of stillbirth prevention are limited [23].
A screening test that detects women at increased risk for stillbirth also demands an 
effective intervention among those high-risk women. If the intervention is ineffective there is not 
much point in screening for the condition. Therefore, when results of tests of fetal well-being are 
assessed, possible interventions, often induction of labor or Caesarean section have to be 
included in the analysis. Neonatal mortality rates have to be included as well since they most 
probably will be affected by the interventions, especially scheduled deliveries in the premature 
period. A model showing that losses might be prevented by structured fetal assessment and 
routine induction of labor among women at increased risk for stillbirth has been described by 
Fretts et al. [73]. However, available tests of fetal well-being do not have the predicted values 
assumed in this model [38]. Controversial is that the last decades early stillbirths (<28 gestational 
weeks) have been the most difficult to prevent, but most forms of antenatal testing are 
recommended implemented from gestational weeks 32-34.  
The oldest method to assess fetal well-being, and the most commonly used, is maternal 
perception of fetal movements [227]. However, the efficacy of organized fetal movement 
counting, with pre-defined alarm limits, to prevent stillbirths in the general population is 
controversial. Moore et al. reported a considerate reduction in stillbirth rates during a 7 month 
study period of prospective evaluation of a fetal movement screening program and concluded 
that the count-to-ten fetal movement screening was simple and effective in reducing the stillbirth 
rate [228]. Results of randomized controlled trials in mixed-risk populations have been 
inconsistent, but the authors seem to agree that fetal movements probably reflect fetal well-being 
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and that awareness among pregnant women regarding fetal movements is wise [229,230].
Studies on the efficacy of fetal movement counting are difficult to conduct, since study 
participation automatically raises awareness regarding fetal movements as was demonstrated in 
one study that showed decreased total stillbirth rate in both study  groups in the study period 
[229].  However, Frøen et al. has demonstrated an increased risk of IUGR, fetal distress in labor, 
and stillbirth in low-risk pregnancies with decreased fetal movements [231]. Further research is 
needed regarding the role of maternal assessment of fetal movements, especially in high-risk 
pregnancies, but increased awareness by recommending women to count fetal movements on a 
daily basis has been associated with significant benefits [227].
Several medical treatments for certain causes of antepartum stillbirth have been assessed, 
of which none is in routine practice [38]. Low molecular weight heparin might be effective in the 
case of thrombophilia but no high quality data exist on the effects, although studies are being 
conducted. Low molecular weight heparin and low dose acetylsalicylic acid are currently only 
recommended for the prevention of recurrent pregnancy loss in women with APAs [195,232-
234].
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3.   Aims of the study 
The aims of the current thesis were:
 To estimate the incidence of IUFD in a Norwegian population.
 To assess socio-demographic and clinical risk factors for IUFD, by the use of two 
different control groups with different selection of variables.
 To evaluate changes in risk estimates by different control selection.
 To classify stillbirths in a Norwegian study-population according to the CODAC
classification of perinatal deaths, and to estimate risk factors according to cause of death.
 To investigate the association between APAs and a history of IUFD.
 To investigate the association of inherited thrombophilia and IUFD.
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4.   Material and methods  
This thesis is based on an epidemiologic study of women with IUFD. It was conducted in two 
parts. The first part (papers I and IV) was an epidemiologic retrospective case-control study 
focusing on incidence and classification of stillbirths and sociodemographic and clinical risk 
factors. Study subjects in this part of the study were women with IUFD and two different control 
groups comprising women with live births, one including all women with life births in the same 
area and time period as the cases and the other comprising conditionally selected controls from 
one hospital. The second part of the study (papers II, III and IV) was a case-control study 
investigating the association of acquired or inherited thrombophilia and IUFD. The study 
subjects were women with a history of IUFD and controls with live births only, who agreed to 
participate and donated blood samples and answered questionnaires.
The present study was a part of a larger hospital-based case-control study: the Venous 
Thromboembolism In Pregnancy (VIP) study and was registered as a clinical observational study 
at www.clinicaltrials.gov, registration number NCT00856076. The other part of the study 
investigated the epidemiology and risk factors for pregnancy associated venous thrombosis. Data 
on clinical and biochemical risk factors for venous thrombosis related to pregnancy have been 
published previously [163,235-238].
4.1   Identification of cases
4.1.1 First part of the study (papers I and IV)
All women with a diagnosis of IUFD, from January 1st 1990 through December 31st 2003, at the 
Departments of Obstetrics at the Oslo University Hospital Ullevål (OUH), Oslo, and Akershus 
University Hospital (AHUS), Nordbyhagen, Norway, were identified retrospectively by search
for selected codes of the WHO’s ICD versions 9 or 10, that were registered in the patient 
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administrative systems at the respective hospitals. The codes searched for were; ICD-9: 656.4 
IUFD and ICD-10: O36.4 IUFD. We identified 434 possible cases of IUFD defined as fetal death 
in singleton or duplex pregnancies at > 23 completed gestational weeks or birthweight > 500g 
irrespective of gestational age. The medical records were retrieved and reviewed for validation of 
the diagnosis of IUFD. The records were non-retrievable for eight cases and 49 were wrongly 
diagnosed, leaving us with 377 women with a verified diagnosis of IUFD (Figure 4.1). 
Figure 4.1. Flowchart of the selection of cases and controls in the first part of the study.
Registry-
based controls
Cases
1 229
Hospital-based 
controls
434 92 476
1 215 377 87 395
8 – non-retrievable records
49 – wrongly diagnosed
4 106 – gestational age 
unknown
235 – gestational age <23 w
161 – no data on parity
71 – maternal age < 16 or
>44 yrs
2 – maternal age unknown
9 – IUFD
5 – maternal age < 16 or
>44 yrs
506 – IUFD
4.1.2 Second part of the study (papers II, III and IV)
The 377 women with a verified diagnosis of IUFD in singleton or duplex pregnancies from the 
first part of the study were eligible for participation in the second part. Additionally two women
with IUFD at the study hospitals in the study period, but not identified earlier, who contacted the 
study after having heard of it through the Norwegian SIDS and Stillbirth Society were eligible 
for participation. The women’s unique personal identification numbers (given to each Norwegian 
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citizen at birth or on immigration) were merged with census data (Statistics Norway, Oslo, 
Norway). Women who had emigrated, died, or had an invalid, unknown or foreign address, were 
excluded from the study, leaving us with 346 cases eligible for study participation (Figure 4.2).
Figure 4.2. Flowchart of the selection of cases and controls in the second part of the study.                
The eligible participants were approached during 2008 by a letter outlining the purpose of 
the study. Those interested contacted us by e-mail or telephone to schedule an appointment to 
donate a blood sample and to answer a questionnaire. One woman did not donate a blood sample 
and was therefore excluded from the study. After two reminders the final case population 
comprised 105 women (Figure 4.2).
4.2   Selection of controls
4.2.1 First part of the study (paper I and IV)
Two control groups with different selection criteria and with different sources of information on
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potential risk factors were chosen for comparison.
4.2.1.1 Facility-based controls
The Norwegian Medical Birth Register (MBR) comprises data from compulsory notification of 
all births after 16 weeks of gestation, registered at each hospital and forwarded to the MBR. 
Information from the MBR revealed 92 476 singleton or duplex deliveries in the study period at 
the two study-hospitals. Excluded from analysis were women with no data for maternal age 
(n=2), women younger than 16 years or older than 44 years since none of the cases were in those 
age groups (n=71), women who had missing data on gestational age (n=4 106), women at 
gestational age less than 23 weeks in combination with fetal weight < 500g (n=235), women 
with no data on parity (n=161), and women with IUFD in the index pregnancy (n=506). The 
remaining 87 395 women served as the facility-based controls (Figure 4.1).  
4.2.1.2 Selected controls
In all 1 229 women with live singleton or duplex births at OUH in the study period, were 
selected as controls for both arms of the VIP-study [235]. For each woman with venous 
thrombosis in the pregnancy or the post-partum period within the study period four women, 
giving birth at the same time, were selected from the MBR as possible controls. The two women 
first listed served as controls, but if one or both of their medical records were not retrievable, the 
third and/or fourth women were chosen as control(s). We excluded three women older than 44 
years, two younger than 16 years and nine women with IUFD in the index pregnancy, leaving us 
with 1 215 women as selected controls (Figure 4.1). 
4.2.2 Second part of the study (papers II, III and IV)
The 1 229 women selected as controls for the VIP-study were initially invited to participate in 
the venous thrombosis part of the study. The eligible participants were during 2006 approached 
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by a letter outlining the purpose of the study. Those interested contacted the study by e-mail or 
telephone to schedule an appointment to donate a blood sample and to answer a questionnaire. A
total of 353 (28.7%) women agreed to participate and donated blood samples and answered 
questionnaires. At the same time they agreed on receiving an invitation and a new questionnaire 
at a later time for participation in the IUFD-part of the study. Of the 353 women nine women had 
a history of IUFD and 18 had emigrated, died, or had an invalid, unknown or foreign address
and were excluded from the study, leaving 326 women eligible for participation. They received 
an invitation together with a new questionnaire by postal mail. After two reminders 262 women 
had returned the questionnaire and thus comprised the control population (Figure 4.2).
4.3 Collection of data
4.3.1   Sociodemographic and clinical variables 
The cases and the selected controls were identified at the participating hospitals. The medical 
records were retrieved and reviewed for validation of the diagnosis of IUFD and information on 
demographics, general health, obstetric history, index pregnancy, delivery, post-mortem 
examination of the fetus, histological examination of the placenta, and laboratory data. 
Individual data were transferred to a case-report-form (CRF). The CRFs were scanned, 
consistency analysis run and invalid data entries corrected after a review of relevant medical 
records. The data for the facility-based control group were provided by the MBR. 
Risk factors assessed were delivery hospital, period of delivery, maternal age, parity, 
marital status, assisted reproductive therapy, smoking habits, previous medical disorders (type 1 
diabetes mellitus, essential hypertension and thyroid disease), twin pregnancy, gestational 
diabetes, gestational hypertensive disorders, placental abruption, placenta previa, premature 
rupture of membranes, SGA and gestational age at delivery.
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The period of delivery was divided in two groups (1990-1999 and 2000-2003). Maternal
age was analyzed either in four (< 29, 30-34, 35- 	 
    > 35) groups. 
Parity was also analyzed in either four (0, 1, 2, or > 2) or two (0 or > 1) categories. Marital status 
was analyzed in two categories (single or married and cohabiting) and smoking was defined 
according to smoking status at first antenatal visit (smoker or non-smoker). The assisted 
reproductive therapy variable included in vitro fertilization (IVF) and intracytoplasmic sperm 
injection (ICSI) (yes or no). The expected date of delivery was estimated by routine ultrasound 
examination at 16 to 18 gestational weeks for 73% of the women. In the absence of ultrasound 
data, gestational age was determined by the first day of the last menstrual period. The time of 
fetal death was determined by the gestational age at diagnosis. A diabetes variable was analyzed 
in three categories (pre-gestational diabetes (DM), gestational diabetes (GD) or no diabetes), but 
in Paper IV it was analysed in two categories (diabetes or no diabetes). The hypertensive 
disorder (HD) variable was also analysed in three categories (all hypertension (HT) (essential or 
gestational), preeclampsia (PE) (all forms) or no HD). Validated population-based growth charts 
were used to determine whether the fetus was SGA, which was defined as birthweight below the 
2.5th percentile for gestational age at birth. Other variables were dichotomized in categories with 
or without the relevant condition. Individuals with missing data were allocated to the reference 
group for the respective variables. Data on smoking, SGA and thyroid disease were not available 
for the facility-based controls. In model C (see chapter 4.4.1, page 67) of the multivariate 
analyses an interaction was revealed between SGA and HD and therefore a new variable 
combining the two conditions was created, comprising four categories: 1) no HT, no PE, no SGA 
(reference group), 2) HT or PE, no SGA, 3) HT or PE with SGA and 4) SGA, no HD.
 63 
 
4.3.2   Classification of stillbirths
The primary cause of fetal death (COD), and associated conditions (AC) when appropriate were
assigned by the author according to the CODAC classification for perinatal deaths (described in 
more detail in chapter 2.1.4.1, page 22-25) [60] after reviewing all available data on each case.
Two of the main groups were not relevant for coding in this study (group 9=termination and 
group 1=neonatal death). 
4.3.3   Placenta histology
The results of the original placenta examinations, available in the medical journal for 93% 
(351/377) of the cases, were reviewed. This revealed that the placentas had originally been 
evaluated by general pathologists. No standardized protocols for macro- or microscopic 
evaluation or sampling of placental tissue were in use in the study period and the reports were 
inconsistent. In most cases sections had been sampled from the umbilical cord, the membranes 
and minimum two sections from placental tissue from areas with and without focal parenchymal 
pathology. The tissue sections had routinely been fixed in formalin, processed and embedded in 
paraffin blocks, and 3.5 μm sections stained with Hematoxylin-Eosin (HE).  For more uniform 
placenta investigations, to obtain a more accurate classification of causality, the original placenta 
specimens were retrieved and reassessed, if available. 268 specimens were retrievable and were
reassessed by two experienced pathologists (Borghild Roald and Gitta Turowski) with special 
interest in placental pathology at the Department of Pathology, OUH Ullevål. They were blinded 
regarding the identification and clinical details of the stillbirths. Specimens with microscopic 
signs of acute or chronic villitis and/or intervillositis were immunostained with a standard panel 
of antibodies to T-cell- and histiocytic markers. If the specimens were not available for 
reassessment the original placenta histological descriptions (n=99) were used. A histological 
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description of the placenta, either the reassessment or the original one, was available for 367/377 
(97.3%) of the cases. Placenta information was most often missing from the controls since
histological examination of the placenta is rarely carried out among normal birth giving women.
4.3.4   Blood sampling and analysis
The cases donated blood samples in 2008 and the controls in 2006. Blood was collected in 5 mL 
Vacutainer tubes (Becton-Dickinson, Meylan-Cedex, France) containing 0.5 mL buffered citrate 
(0.129 mol/L) and 5 mL Monovette tubes containing ethylenediaminetetraacetic acid (EDTA)
(Sarstedt, Nümbrecht, Germany). The Monovette EDTA tubes were frozen immediately and the 
tubes with buffered citrate were centrifuged at 2000g for 15 minutes within 1 hour, and plasma 
aliquots frozen and kept at -70 °C until assayed. 
The blood was analysed for LA, aCL, anti-2GP1, FVLeiden, prothrombin polymorphism, 
AT, PC and PS. The assays were performed at the Hematologic Research Laboratory, 
Department of Hematology, OUH Ullevål. LA was identified using validated in-house lupus 
ratio (LR) tests, which are automated, quantitative, integrated tests for LA [239,240]. Two LR 
tests were performed, one based on the activated partial thromboplastin time (LR-APTT) and the 
other on the Russell’s viper venom time (LR-RVVT). The tests were performed in a 1:1 mixture 
of patient plasma and pooled normal plasma. For each test two coagulation times were measured, 
one with a reagent with low and the other with a reagent with high phospholipid concentrations.
The ratio between the two coagulation times (low phospholipid/high phospholipid concentration) 
was divided by the corresponding ratio obtained with pooled normal plasma. The final ratio is 
defined as the LR of that patient's plasma [240]. The reagents were made from different 
concentrations of natural phospholipids (crude cephalin, generously provided by Dr. Tore 
Janson, Axis-Shield PoC AS, Oslo, Norway). In the APTT-based assay, a constant concentration 
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of ellagic acid (Sigma-Aldrich, St. Louis, Missouri, USA) was used as an activator of 
coagulation. In the RVVT-based test, Russell’s viper venom (RVV) (Sigma-Aldrich, St. Louis, 
Missouri, USA) activates factor X directly. The 99th percentile of the LR of the control group 
was chosen as the upper reference limit, and was 1.22 for the APTT-based LR test and 1.19 for 
the RVVT-based test. Women with LR above the upper reference limit for one or both of the 
LR-tests were considered LA positive.
aCL IgG and IgM isotypes were analyzed with in-house enzyme-linked immunosorbent 
assays (ELISA), essentially as described by Gharavi et al. [241]. We used serial dilutions of an 
in-house control drawn from a strongly aCL positive patient, which were standardized against 
Harris’ commercial standards (American Diagnostica Inc., Stamford, CT, USA). Values for IgG 
and IgM isotypes of aCL were reported in GPL and MPL units, respectively. The cut-off values 
for a positive test were defined by the 99th percentile of the values of the control group, and were
10.7 for aCL IgG and 23.7 for aCL IgM. Women with values above the cut-off limits for aCL 
IgG and/or aCL IgM were considered as aCL positive. 
Anti-ß2GP1 IgG and IgM were assayed with commercial ELISA kits (QUANTA LiteTM
2 GP1 IgG/IgM, INOVA Diagnostics Inc., San Diego, USA) for semi-quantitative 
determination. Results were expressed in standard IgG and IgM anti-ß2GP1 units, SGU and 
SMU, respectively. The 99th percentiles of the values of the control group were defined as upper 
reference limits, and were 6.5 for anti-ß2GP1 IgG and 30.3 for anti-ß2GP1 IgM. Women with 
values above the upper reference limits for IgG and/or IgM were considered anti-ß2GP1 positive.
 DNA was extracted using a DNA isolation kit I large volume (Roche Diagnostics, Basel, 
Switzerland) using Magna Pure (Roche Diagnostics). FVLeiden and the prothrombin
polymorphism were detected with FVLeiden Mutation Detection and Prothrombin Mutation
Detection kits (Roche Diagnostics), respectively, run on a real-time polymerase chain reaction
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(PCR) - analyser (LightCycler 2.0, Roche Diagnostics).
AT and PC activities and free PS quantities (antigen assay) were analyzed with 
commercial kits, Coamatic® Antithrombin, Coamatic® Protein C and HemosILTM Free Protein 
S (Chromogenix, Lexington, MA, USA). AT activity < 80% and PC activity < 70% were defined 
as deficient. PS values were expressed as percentage of normality. The reference limit for PS
was defined as two standard deviations below the mean of the control group or 53.7%. Women 
with values below the reference limit were defined as PS deficient. One woman with PS and one 
with both PC and PS below cut-off limits reported use of warfarin medication and were therefore 
excluded from all analyses including inherited thrombophilia (n = 103).
4.3.5 Questionnaire
In the second part of the study (papers II and III) the participants answered questionnaires 
regarding socio-demographic factors, obstetrical history, general and psychological health, and 
quality of life at the present time. The cases answered the questionnaire on site at the time of the 
blood sampling, but the controls recieved and returned the questionnaire by postal mail. The 
questionnaires were scanned, consistency analysis run and invalid data entries corrected after a 
review of the relevant questionnaires.
4.4   Statistical analysis
Incidence was estimated as the number of IUFDs per thousand deliveries with 95% confidence 
interval (CI). Prevalences were reported in percentages. Risk factors were analysed by 
comparing prevalences of potential risk factors between cases and controls with chi-squared
tests, Fisher’s exact tests and univariate and multiple logistic regression. Results of risk factor 
analyses were presented as crude odds ratios (OR) and adjusted OR (aOR) with 95% CIs. 
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Interactions between significant factors were tested at 95% significance level (p < 0.05).
Significance level was set at p < 0.05. All data was analyzed using the Statistical Package for 
Social Science version 16.0 or 18.0 (SPSS Inc, Chicago, Il, USA).
4.4.1   Paper I
We assessed risk factors for IUFD by comparing cases and controls in three multiple logistic 
regression models (table 5.1, page 70).  Model A compared the cases with facility-based 
controls. Variables included in the model were chosen based on the significance of each variable 
in the univariate analysis and variables moderately associated with the outcome (p-value < 0.15) 
were considered for inclusion into the model. The significance of each variable and effects on the 
stability of the model, were investigated by backward and forward stepwise logistic regression.
Model B explored the same variables as included in Model A, but using the selected controls in 
the comparison, whereas Model C compared the cases with selected controls including additional 
variables. The additional variables in Model C were variables, for which there were no data 
among the facility-based controls, only among the selected controls. The additional variables 
were added to model C based on the same principles as described for Model A.
Gestational age
The probability of IUFD according to gestational age was defined by the number of events          
(number of IUFDs) divided by the number of pregnancies at risk at a defined gestational age. 
The population at risk in a given gestational week consisted of all ongoing pregnancies. The 
estimates of probability for IUFD according to gestational age were derived from the following: 
the number of ongoing pregnancies at the beginning of gestational week n (Pn), the number of all 
births in gestational week n (Bn), and the number of IUFDs in gestational week n (Sn). The 
conditional probability of IUFD at gestational week n (PSn) was estimated by the number of 
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IUFDs in that week, divided by the number of ongoing pregnancies at the beginning of the week 
minus half the births in the given week as in this equation [114]:
     PSn = Sn/(Pn – (0,5 x Bn)).
Relative risk of IUFD in a given gestational week was derived from the conditional probability 
of IUFD in that week divided by the conditional probability of IUFD in gestational week 40. 
4.4.2   Paper IV
For detection of potential variations in risk factors according to cause, risk factors were analysed 
by comparing prevalences in different causal groups with prevalences in the control group. The 
eight actual COD groups were combined and analysed in three groups: placental causes (N=190), 
unknown causes (N=73), other causes (the remaining six causal groups combined in one) 
(N=114). ORs for each risk factor were adjusted by all the other relevant risk factors in a 
multiple logistic regression model. Variables included in the regression models were chosen 
based on the same principles as described in chapter 4.4.1. The Results were presented as 
percentages, ORs and aORs with 95% CIs.
4.5   Ethical aspects
The Regional Committee for Medical Research Ethics, Region East, Norway, approved the 
study. Authorization for the use of information from medical records for research purposes was 
obtained from the Norwegian Ministry of Health and Social Affairs. The Norwegian Data 
Inspectorate approved the use of data comprising sensitive personal health information, and the 
merging of clinical and register data by using the unique 11-digit personal identification number.
Women participating in the study by answering questionnaires and donating blood samples
signed a written informed consent.
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5.   Summary of results
5.1   Incidence and risk factors of fetal death in Norway: a case-control study, Paper I
In Paper I we studied the incidence of IUFD and socio-demographic and clinical risk factors, 
among the cases and two differently selected control groups. 
The incidence of IUFD after 22 gestational weeks was 4.1 per 1000 deliveries (95% CI 
3.7-4.5) and did not change significantly over the study period (Figure 5.1). For comparison, the 
incidence at or after 28 gestational weeks in our material was 3.3 per 1000 (95% CI 2.9-3.6).
Figure 5.1. Yearly incidence of IUFD at OUH Ullevål and AHUS 1990-2003. 
 
There was a significant difference in the incidence of IUFD between the two hospitals; 
4.7 (95% CI 4.1-5.3) per 1000 births at OUS and 3.4 per 1000 (95% CI 2.8-4.0) at AHUS. When 
comparing with facility-based controls in a multivariate analysis (Table 5.1, Model A) maternal 
age over 39, single civil status, twin pregnancy, hypertensive disorders, pre-pregnancy and 
gestational diabetes mellitus, placental abruption and placenta previa were significant risk factors
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Table .5.1 Risk factors for IUFD by different control groups and variable selection. Adjusted 
odds ratios (aOR) with 95% confidence intervals (CI).
 Model A Model B Model C
 aOR (95% CI) aOR (95% CI) aOR (95% CI)
Cases = N 377 377 377
Controls = N 87 395 1 215 1 215
Time period
1990 – 1999
2000 – 2003 n.s. n.s.
Age (years)
< 29
30-34
35-39
> 40
0.9 (0.7-1.1)
=Reference
1.3 (0.9-1.7)
2.5 (1.6-4.0)
1.0 (0.8-1.3)
=Reference
1.0 (0.7-1.4)
0.9 (0.6-1.7) 
0.9 (0.7-1.3)
=Reference
1.1 (0.7-1.6)
0.7 (0.3-1.4)
Parity
0
1
2
> 2
n.s. n.s.
Twin pregnancy 1.6 (1.0-2.4) 3.3 (1.8-6.0) 2.9 (1.4-6.0)
Civil status 
Not married/cohabiting 1.9 (1.4-2.6) 1.9 (1.3-2.8)    1.3 (0.8-2.1)
Hypertensive disorders (HD)
    Preeclampsia (PE)
Hypertension (HT)
2.9 (2.2-3.9)
1.9 (1.2-2.8)
5.6 (3.8-8.7)
1.7 (1.2-2.4)
1.3 (0.8-2.2) 
2.1 (1.3-3.3)
HD/ SGA
   No HD, no SGA
   HD, no SGA
   HD with SGA
   SGA, no HD
=Reference
1.6 (1.0-2.6)
11.5 (5.2-25.3)
51.5 (27.4-96.7)
Diabetes
Pre-pregnancy diabetes
Gestational diabetes
4.0 (1.9-8.8)
2.5 (1.1-5.7)
4.8 (1.5-15.4)
1.8      (0.7-4.9)
5.0 (1.4-17.5)
3.0 (1.1-8.4)
Placental abruption 22.0 (15.8-30.8) 16.0 (7.9-32.5) 15.4 (7.3-32.3)
Placenta previa 3.4 (1.3-8.8) 2.8      (0.9-8.7) 3.4 (1.0-11.9) 
Smoking 2.6 (1.9-3.7)
Thyroid disease 4.6 (2.0-10.6)
Model A: Cases compared with facility-based controls adjusted for hospital, age, multiple pregnancy, civil status, 
hypertensive disorders, diabetes, placental abruption, and placenta previa. Model B: Cases compared to selected 
controls, same variables as in model A. Model C: Cases compared to selected controls with additional variables, 
adjusted for age, multiple pregnancy, civil status, hypertensive disorders/SGA, diabetes mellitus, placental 
abruption, placenta previa, smoking, and thyroid disease. 
n.s.: not significant.
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for IUFD. When comparing with the selected controls, some additional variables were available 
for analyses (Table 5.1, Model C). The following factors were significant in the final model: twin 
pregnancy, hypertensive disorders, SGA, pre-pregnancy and gestational diabetes mellitus, 
placental abruption, placenta previa, smoking and thyroid disease. SGA and placental abruption 
were the strongest risk factors for IUFD. Hypertensive disorders were of low risk if not 
associated with SGA. Other risk factors were of low to moderate risk. Advanced maternal age 
was a significant risk factor when compared with facility-based controls, but not when 
comparing with the selected controls and the risk estimates for hypertension were higher when 
comparing with the facility based controls. Overall, the risk estimates pointed in the same 
direction independent of control-group. 
Gestational age
Figure 5.2. Relative risk of IUFD with the conditional risk at 40 gestational weeks as a 
reference.
The relative risk (RR) of IUFD in each gestational week, compared with the risk at 40 
gestational weeks, is displayed in Figure 5.2. The RR increased gradually from week 36-37, with 
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RR 1.3 (95% CI 0.8-2.2), 1.4 (95% CI 0.6-3.2) and 2.9 (95% CI 0.7-12.1) in weeks 41, 42 and   
> 42 respectively. We did not find advanced gestational age (> 42 gestational weeks) to be a
significant risk factor for IUFD. 
5.2   The association of antiphospholipid antibodies with intrauterine fetal death: a
        case-control study, Paper II
In Paper II we studied the prevalences of APAs and their association with a history of IUFD. The 
APAs studied were: LA, aCL (IgG and IgM), and anti-ß2GP1 (IgG and IgM). The study 
population consisted of 105 women with a history of IUFD and 262 controls with life births 
only.
Table 5.2. Prevalence of APAs (%) and ORs with 95% CIs for the association of APAs with 
IUFD.
Variable Cases
N= 105
% (n)
Controls
N =262
% (n)
OR 95% CI
APA positive – 	 9.5 (10) 5.0 (13) 2.0 0.9-4.8
LA positive – 	 4.8 (5) 1.1 (3) 4.3 1.0-18.4
Anti- ß2GP1 positive 4.8 (5) 1.5 (4) 3.2 0.8-12.3
aCL positive 3.8 (4) 2.3 (6) 1.7 0.5-6.1
 
Among women with a history of IUFD 9.5% were positive for at least one APA test
compared to 5.0% of the controls (Table 5.2). Having a single positive APA test was not 
significantly associated with IUFD (OR 1.5; 95% CI 0.6-4.0), whereas positivity for a 
combination of more than one APA-tests produced higher odds (OR 7.9; 95% CI 0.8-76.5), but 
nevertheless not a significant association. Women with a history of IUFD were significantly 
more often positive for LA compared to controls with live births only (OR 4.3; 95% CI 1.0-
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18.4). Dividing the LA positive women into those positive for LA only and those positive for 
aCL and/or anti-ß2GP1 in addition to LA revealed that the risk related to LA seemed to be 
confined to women positive for LA in combination with other APA. Being positive for anti--
GP1 or aCL alone was not significantly associated with a history of IUFD after 22 weeks.
5.3   The association of inherited thrombophilia and intrauterine fetal death: a case-
         control study, Paper III
In Paper III we studied the association of inherited thrombophilia and IUFD. The following 
thrombophilias were investigated: FVLeiden, prothrombin polymorphism, AT-, PC- and PS-
deficiencies. The study population consisted of 103 women with a history of IUFD and 262 
Table 5.3. Prevalences of inherited thrombophilia (%) and ORs with 95% CIs for the association 
of thrombophilia with intrauterine fetal death, compared to controls. 
Variable Cases
     N= 103
% (n)
Controls
    N =262
% (n)  
OR 95% CI
Factor V Leiden 10.7 (11) 7.6 (20) 1.4 0.7-3.1
Prothrombin polymorphism 5.8 (6) 1.5 (4) 4.0 1.1-14.4
Antithrombin deficiency 1.0 (1) 0 (0) - -
Protein C deficiency 1.0 (1) 1.1 (3) 0.8 0.09-8.2
Protein S deficiency 1.9 (3) 2.3 (6) 0.8 0.17-4.3
Any inherited thrombophilia 18.4 (19) 11.8 (31) 1.7 0.9-3.1
	

	 1.9 (2) 0.8 (2) 2.6 0.4-18.5
controls with live births only. 18.4% of the cases and 11.8% of the controls were positive for at 
least one inherited thrombophilia (Table 5.3). Women with a history of stillbirth after 22 
gestational weeks were more often carriers of the G20210A prothrombin polymorphism 
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compared to women with live births only (OR 4.0; 95% CI 1.1-14.4). FVLeiden, AT-, PC- or PS-
deficiencies were not significantly associated with IUFD after 22 weeks of gestation. Two cases 
(1.9%) and two controls (0.8%) had a combination of two inherited thrombophilias.  
5.4   Classification of stillbirths by cause of death and risk factor analysis - an observational 
         case-control study, Paper IV
In Paper IV we classified the stillbirths by cause according to the CODAC classification of 
perinatal deaths and studied socio-demographic, clinical and thrombophilic risk factors in 
different causal groups. The study populations comprised 377 cases and 1 215 controls or, in the 
case of thrombophilic risk factors, 105 cases and 262 controls.
A main COD (Level I) according to CODAC was assigned to all the cases (N=377) and 
was placental in 50.4% of the cases, unknown among 19.4% and infectious in 12.2%. Other 
causes were: intrapartum (0.5%), congenital anomalies (6.1%), fetal (2.1%), cord (8.9%) and 
maternal (1.3%). The largest subgroups (level II of the main COD) within placental causes were; 
abruption or retroplacental hematoma (32.1% of placental causes, 16.2% of all stillbirths) and 
infarctions and thrombi (35.3% of placental causes and 17.8% of all stillbirths). These two 
groups were responsible for 34% of all IUFD after 22 gestational weeks.
 An AC was assigned to 72.4% (273/377) of the cases. The most frequent ACs were;
placental in 92/377 (24.4%), cord in 51/377 (13.5%) and associated perinatal conditions in 
55/377 (14.6%). A placental AC was assigned to 68 (18% of all cases) with a non-placental 
COD. Thus 258/377 (68%) of all cases had either a placental COD or placental ACs. Among the
cases with an unknown cause of IUFD, 35.6% (26/73) had a placental associated condition.
To detect socio-demographic and clinical risk factors 377 cases classified in different 
causal groups were compared with 1 215 controls. Smoking and SGA were significant 
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Table 5.4. Risk factors analyses, cases according to main COD compared to controls. Adjusted 
odds ratios (aOR) with 95% confidence intervals (CI).
                               COD
Variable
Placenta 
         N=190
Unknown
N=73
Other
N=114
All cases
N=377
aOR 
(95% CI)
aOR 
(95% CI)
aOR
(95% CI)
aOR 
(95% CI)
Civil status
Not married/cohabiting 2.1 (1.1-3.9)
Twin pregnancy
3.6 (1.3-9.4) 5.0 (1.5-16.0) 2.2 (0.6-8.0) 3.0 (1.4-6.3)
Hypertensive disorders
Preeclampsia/eclampsia
Hypertension
0.5 (0.2-1-1)
2.2 (1.0-4.8)
0.2 (0.06-1.0)
3.5 (1.5-8.0)
0.2 (0.07-0.8)
1.0 (0.3-2.9)
0.6 (0.3-1.2)
1.9 (1.1-3.4)
Diabetes
3.5 (1.1-11.3) 8.7 (3.0-25.4) 2.9 (0.8-10.8) 3.8 (1.7-8.4)
Placental abruption
42.0 (19.4-91.0) - 1.4 (0.2-11.5) 16.1 (7.6-33.9)
Smoking (at first visit)
2.5 (1.6-3.9) 3.7 (2.1-6.6) 2.5 (1.5-4.1) 2.6 (1.9-3.8)
Small-for-gestational age 
47.9 (26.6-86.1) 28.6 (12.8-63.6) 38.6 (19.9-74.8) 32.9 (20-54.2)
Thyroid disease
5.5 (2.0-15.6) 3.8 (0.8-18.0) 5.5 (1.7-17.6) 4.8 (2.1-11.0)
Each variable adjusted for the all the other variables in each logistic regression model.
risk factors in all causal groups. Twin pregnancy, hypertension and diabetes were detected as
significant risk factors among women with IUFD of placental or unknown causes. Placental 
abruption, not surprisingly, was a significant a risk factor in the placental group only and single 
civil status only among women with IUFD of other causes. Thyroid disease was associated with 
an increased risk of stillbirths of placental and of other causes (Table 5.4).  
The 105 cases and 262 controls who donated blood samples for the biomarker study were 
equally distributed in the main COD groups as the whole study-population (47.6% with placental 
and 20% with unknown causes).
Inherited thrombophilia, a composite result, was significantly associated with IUFD of 
placental causes, OR 2.2 (95% CI 1.0-4.7) and the prothrombin polymorphism was more
 76 
 
Table 5.5. Prevalences of acquired and inherited thrombophilia by different causes of stillbirth.
                                  COD
Variable
All
N=105
*N = 103
Placenta
N = 50
*N=49
Unknown 
N = 21
*N=21
Other
N = 34
*N=33
Controls 
N =262
% (n) % (n) % (n) % (n) % (n)
*Factor V Leiden 10.7 (11) 14.3 (7) 14.3 (3) 3.0 (1) 7.6 (20)
*Prothrombin polymorphism 5.8 (6) 8.2 (4) 0 6.1 (2) 1.5 (4)
*Antithrombin deficiency 1.0 (1) 0 0 3.0 (1) 0
*Protein C deficiency 1.0 (1) 0 0 3.0 (1) 1.1 (3)
*Protein S deficiency 1.9 (2) 2.0 (1) 0 3.0 (1) 2.3 (6)
*Any inherited thrombophilia 18.4 (19) 22.4 (11) 14.3 (3) 15.2 (5) 11.8 (31)
LA 4.8 (5) 4.0 (2) 4.8 (1) 5.9 (2) 1.1 (3)
aCL 3.8 (4) 2.0 (1) 4.8 (1) 5.9 (2) 2.3 (6)
Anti- ß2GP1 4.8 (5) 6.0 (3) 0 5.9 (2) 1.5 (4)
Any APA 9.5 (10) 6.0 (3) 9.5 (2) 14.7 (5) 5.0 (13)
*Any thrombophilia 27.2 (28) 28.6 (14) 23.8 (5) 27.3 (9) 16.4 (43)
*Two women reported use of Warfarin and were therefore excluded from all analyzes of inherited thrombophilias.
prevalent among women with placental COD and other causes (Table 5.5), but statistically 
significant only in the group of placental causes, OR 5.7 (95% CI 1.4-23.8). The prevalence of 
FVLeiden was double among women with placental or unknown COD compared to the controls, 
although this did not reach statistical significance. Being positive for APAs was significantly 
associated with a history of IUFD of other causes (OR 3.3; 95% CI 1.1-9.9). Similar proportions, 
4.0 – 5.9%, of women in all causal groups were LA-positive, compared to 1.1% of the controls, 
but the association did not reach significance in any separate causal group although the ORs in 
the different groups were in the range 3.6 – 5.4.
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6.   Methodological considerations
6.1   Paper I and IV
6.1.1   Identification of cases
The cases were identified by ICD codes in the patient administrative systems at the participating 
hospitals. It is possible that some cases were not detected by this method as inaccurate coding is 
probably unavoidable. However, diagnoses registered in the patient administrative systems are 
easily verified by accessing the medical records and falsely diagnosed IUFDs were thus 
excluded. Diagnoses of other conditions in the medical history or related to the pregnancy could 
be verified as well. Another possibility would have been identifying the cases in the MBR, but 
IUFD in the MBR is defined as fetal loss after 16 gestational weeks and underreporting of 
stillbirths is a known problem [personal communication: J.F.Frøen, M.D, Ph.D., Norwegian 
Institute of Public Health]. Information in large databases like the MBR is also reported to be 
less accurate than data from medical records [242,243].
We chose to define stillbirth in our study as 23 or more completed gestational weeks or a 
fetus of at least 500 g irrespective of the gestational age. The WHO definition of stillbirth is a 
fetus > 500 g, or 22 or more completed weeks of gestation [13]. Birth weight takes priority over 
gestational age since birth weight is thought to be more reliably reported. However, in many 
instances, especially in high-income countries, the use of the gestational age is preferred. This 
leads to higher reported stillbirth rates as many fetuses weigh less than 500 g at 22 weeks [16].
6.1.2   Selection of controls
Selected controls
The selected controls were selected for both arms of the VIP-study (thrombosis and IUFD). They
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were women, without a known venous thrombosis, delivering at the same time as each case of a
woman with a pregnancy related venous thrombosis. The only exclusion criterion at the time of 
selection was a history of venous thrombosis. We find it unlikely that this selection was a source 
of bias in the first part of our study, when investigating socio-demographic and clinical risk 
factors. However, it could have been a source of bias in the second part of the study, when 
examining the association of thrombophilia and IUFD.
This control group was for practical reasons selected from only one of the study 
hospitals. This might have caused a selection bias as the delivering populations at each of the 
hospitals were not necessarily alike. Our data on maternal age revealed in fact that there probably 
was a selection bias. When we compared the cases with the facility-based controls (all women 
delivering at the study hospitals in the study period), advanced maternal age was a significant 
risk factor for IUFD, not detected when comparing the cases with the selected controls. We 
looked further into this and compared the age distribution of the different control groups and 
found that the selected controls were on average older than the women in the facility-based 
control group. The selected controls did not accurately represent the age of the background 
population from which the cases were selected. However, this did probably not affect the risk 
estimates for the other variables as maternal age was adjusted for in the multivariable analyses. 
Facility-based controls
The facility-based controls were not a selection of women, but represented the entire birth-giving 
population of the study hospitals, from which our cases were extracted and thus comprised the 
“true” demographic distribution. Using them as controls thus minimized or eliminated the risk of 
selection bias making the results more generalizable. But there can be a disadvantage using this 
control group regarding the quality of data extracted from the MBR, as will be discussed later.  
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6.2   Paper II, III and IV
6.2.1   Selection of cases
Table 6.1. Prevalences of social and clinical factors at index pregnancy among cases 
participating and those not.
Variable Cases
participating
N= 105
Cases
Non-participating
N =274
p*
% %
Time period
1990-1999
2000-2003
62.9
37.1
57.7
42.3 n.s.
Age  
< 35
> 35
80.0
20.0
76.6
23.4 n.s.
Parity  
0
1
> 2
52.4
34.3
13.3
51.5
30.7
17.9 n.s.
Civil status (at registration)
Married or cohabiting
Not married/cohabiting
90.5
9.5
85.0
15.0
n.s.
Multiple pregnancy 3.8 6.6 n.s.
Hypertensive disorders
Preeclampsia/ eclampsia
Hypertension
5.7
   4.8
7.7
9.9 n.s.
Diabetes
Diabetes  type 1 or 2
Gestational diabetes
   All diabetes
   1.0
   0.0
1.0
2.2
2.2
4.4 n.s.
Placental abruption 8.6 12.8 n.s.
Placenta previa    1.9 1.1 n.s.
Smoking (at first visit)
Non-smoker
Smoker
71.4
28.6
61.7
38.3 n.s.
Small for gestational age 35.2 35.8 n.s.
Eligible for participation in the second part of the study were 346 women. Of the total 379 with 
IUFD in the study period 105 (28%) agreed to participate. This low response-rate increases the 
risk of selection-bias. We had the advantage of having information from medical records from all
the eligible participants and were thus able to compare the women participating with those not
participating. We found no significant differences in socio-demographic or clinical factors 
between the groups (Table 6.1). Therefore we do not believe that this low participation rate was a 
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basis for a serious selection bias, but it did affect the power of the study. Stillbirth is a 
traumatizing experience which women for various reasons may not wish to be reminded of many 
years after the incidence. Contributing to the low response-rate might also have been the 
inconvenience of having to present at the hospital in order to donate a blood sample and answer 
questionnaires. It is possible that women with negative long-term outcomes to a larger degree 
declined to participate in the study. On the other hand, women that had adequately coped with 
the loss and moved forward may also have found little interest in participating. 
6.2.2   Selection of controls
The 353 controls eligible for the second part of the study were already a selected group, as they 
had donated blood samples two years earlier and at the same time agreed to answer a new 
questionnaire related to this part of the study. The participation rate in this part of the study was 
therefore 74% (262/353), but if taken into account all the 1 215 women originally eligible as 
controls, the participation rate was 21.6%. As for the cases, we had information from medical 
records from all the 1 215 eligible participants. We compared the participating 262 controls with 
the 953 non-participating women.  The participating controls were older, of lower parity, more 
often married or cohabiting, smoked less often and had more often preeclampsia (Table 6.2). 
Other factors were evenly distributed between the groups. We find it unlikely that the prevalence 
of thrombophilia would be affected by these parameters, apart from preeclampsia.   
Thrombophilia is possibly associated with preeclampsia. If so, this would result in a higher 
prevalence of thrombophilia among the participating controls and thus a possible 
underestimation/attenuation of the association between thrombophilia and stillbirth.   
Women with venous thrombosis were excluded from the control group at the time of 
selection. Because of this, it is possible that thrombophilia was less prevalent in the control 
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group than expected in the general population. This could in return result in an overestimation of 
the association between thrombophilia and IUFD.
Table 6.2. Social and clinical factors at index pregnancy among controls participating and those 
not.
Variable Controls
participating
N=262
Controls
Non-participating
N=953
p¤
% %
Time period
1990-1999
2000-2003
60.3
39.7
59.5
40.5 n.s.
Age (at index pregnancy)
   < 35
   > 35
68.3
31.7
77.9
22.1 0.001
Parity
0
1
> 2
50.4
39.3
10.3
48.0
31.6
20.4
n.s.
Ref
< 
0.0001
Civil status (at registration)
Married or cohabiting
Not married/cohabiting
96.6
3.4
90.7
9.3 0.001
Multiple pregnancy 2.7 2.0 n.s.
Hypertensive disorders
Preeclampsia/ eclampsia
Hypertension
7.3
4.6
4.4
4.1
0.035
n.s.
Diabetes
Diabetes  type 1 or 2
Gestational diabetes
   All diabetes
0.0
0.4
0.4
0.5
1.3
1.8 n.s.
Placental abruption 0.8 0.9 n.s.
Placenta previa 0.8 0.6 n.s.
Smoking (at first visit)
Non-smoker
Smoker
91.6
8.4
85.1
14.9 0.007
Small-for-gestational-age 1.5 2.1 n.s.
6.3   The data 
6.3.1   Sociodemographic and clinical variables
An advantage of using data from medical records, rather than from a registry like the MBR, is 
that all information of interest can be extracted and the data are easily validated by reviewing the 
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records. This ensures the quality of the data. The data retained in the MBR is forwarded from 
delivery institutions. Data regarding each delivery is transferred to a standardized form, often by 
the midwife handling the delivery, and then subsequently forwarded to the MBR. Some variables 
of interest might be registered incorrectly or are not registered at all in the database. Normally 
there is not an opportunity for the researchers to validate the data. Thus the information extracted 
from the database is dependent on the information that was recorded at the time of registration.
This would in our study apply an information bias, differentiated between the cases and the 
facility-based controls, since the data are from different sources. Studies have demonstrated that 
data on pregnancy complications like hypertension and gestational diabetes are often 
underreported in databases like the MBR [242,243]. This would lead to an overestimation of the 
association between certain conditions and IUFD when comparing the cases with the facility 
based control group. We believe we have an example of this in our study, as when we compared 
the cases to the facility based controls, the OR’s for the associations of hypertension, 
preeclampsia or gestational diabetes and IUFD were greater than when comparing the cases with 
the selected controls (Table 5.1, page 72, Model A and Model B respectively).
Another advantage of using data from medical records was information on additional 
variables, not provided by the MBR. Information of additional variables is valuable in assessing 
confounding and in detecting co-linearity and interaction. We had an example of this relating to 
the association of single civil status and IUFD. When we compared the cases with the selected 
controls and added smoking to the multiple logistic regression model, single civil status was no 
longer significantly associated with IUFD (Table 5.1, page 72, Model C). We looked further into 
this and found that single women smoked more often than women married or co-habiting. There 
was another example of this with respect to the association of hypertensive disorders (HD) and 
IUFD. We had information on SGA among the selected controls. When we added SGA to the 
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statistical model we detected an interaction between HD and SGA (Table 5.1, page 72 Model C). 
The risk of IUFD related to hypertensive disorders was mediated through SGA, and was low or 
moderate if not accompanied by SGA.
Small-for-gestational-age (SGA)
SGA is not synonymous with intrauterine growth restriction (IUGR), as some SGA-fetuses may 
be constitutionally small while some normal-sized fetuses might be originally large-for-
gestational-age (LGA) that are growth restricted. The choice of what to use in studies often 
depends on what kind of data are available, but SGA is commonly used as an approximate for 
IUGR, as we have done in this study. For identification of SGA it would have been preferable 
with customized growth charts that take into account maternal height, weight, parity, ethnic 
origin and the baby’s gender [129,244]. We used population based growth charts to identify SGA 
since we did not have information on ethnicity and the information on maternal height and 
weight was often missing. The use of population based growth charts is reported to 
underestimate IUGR among preterm births [128]. If this were to be true in our material and the 
prevalence of SGA thus underestimated, the risk estimates for the association of SGA and IUFD 
would have been even higher.  
The time of fetal death in our material was set at the time of diagnosis of the IUFD. Other 
authors have used the time of delivery minus 2 days as the estimated gestational age of IUFD, 
since that length of time is considered the average delay from fetal death to spontaneous or 
induced delivery [48]. By our method it is possible that we have in some cases overestimated the 
gestational age for time of death, which could in turn result in an overestimation of SGA. But it 
is unlikely that the true time of death would have differed more than a few days on average 
which probably has not affected the diagnosis of SGA considerably.
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6.3.2   Placenta histology
We found placenta pathology coded as a COD or an AC among 68% of the stillbirths. This was
not unexpected since all these pregnancies had the very adverse outcome of stillbirth. However, 
there is a possibility that the focus on the placental investigation and placental pathology lead to 
over-diagnosis of placental pathologies. If fewer had been assigned a placental COD it is 
reasonable to believe that a greater proportion would have had an unknown cause. It is reported 
in the literature that a thorough examination of the placenta generally generates higher rates of 
stillbirths with placental causes and reduction in unexplained stillbirths [51,53].
Histological examination of the placentas from the controls would have been desirable.
But, this was a retrospective study, and in the study period placentas were sent to histological 
examination on indication only. The pregnancies of live-born infants were in fewer instances 
pathological and therefore few of these placentas were referred to histological examination. We 
did not evaluate the character of the placental findings among women with different causes or 
risk factors for IUFD since that was not the scope of this study. Reports from other authors 
suggest that placental pathological changes are often non-specific [190].
6.3.3   Classification
The assigned cause of death is a matter of expert opinion of the one who codes. In our study the
classification was carried out by one person only (the author), which might be considered a 
weakness. It is preferable that each case is classified by two individuals and agreement sought in 
cases of inconsistencies. The qualities of the CODAC classification system have been tested and 
reported recently. The inter-observer agreement was reported to be generally fair, with a mean 
kappa of 0.65 [51], but good, with a kappa of 0.82-0.94 when the coding rules were extensively 
followed [60].  The ease of use received the highest scores of the classification systems tested 
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[51]. L.B.H. is an experienced obstetrician and the placenta histological examinations were done
by experienced pathologists so we believe the coding is not a source of great bias. The
distribution in causal groups was in agreement with the distribution in six other high-income 
countries recently reported which supports our findings [27].
6.3.4   Blood sampling and analysis
About 5-7% of healthy pregnant women have been reported to have positive tests for APAs 
[245]. The prevalence of APAs depends on the definition of a positive test. It is recommended by 
international consensus to define the cut-off values by the 99th percentile of the control group
[246,247]. Since by definition 1% of the controls will have a positive result for each test, the 
prevalence of APAs in the healthy population will be influenced by the number of tests
performed. Thus, if six different tests are used, up to 6% of the control/normal population will be 
APA positive. 
The results of the Free PS assay in our study were expressed as percentages of normality, 
with reference values two standard deviations below the mean of the control group (53.7%). The
Haematological Research Laboratory at OUH Ullevål has defined the normal range of free PS to 
be 65-130%, and values under 65% are defined as deficient.  PS concentrations vary depending 
on several factors like age, gender, acquired conditions and the use of oral hormonal 
contraceptive or replacement therapy, which can lead to misdiagnosis of PS deficiency [178-
181]. A report from 2010 demonstrated that lowering the cut-off values for PS and using the 
mean value of the controls minus 2 SD increased the specificity of the assays [182], which is 
why we have chosen to do so in our study.
Collection of blood samples only at a single time point and a long time after the index 
pregnancy are limitations of our study. However, one of the rationales for repeated testing of 
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APAs is to avoid false positive tests due to transiently elevated APAs, which we believe is not a 
concern in the present study, when the samples were collected 3-18 years after the index 
pregnancy. Neither is there reason to believe that any transient APAs should be more prevalent
among the cases than the controls at this time.
6.3.5   Questionnaire
Information from the questionnaire has not been a source for main analyses in any of the four 
publications included in the present thesis. Information from the questionnaires has been used to 
investigate: 1) factors that might influence the results of blood samples as pregnancy, hormonal 
or anticoagulation therapy and 2) prevalence of other incidents that might have similar causes or 
risk factors as stillbirths, especially miscarriages/fetal deaths in the first or second trimester 
before 23 gestational weeks. Information reported in questionnaires is subjected to the memory 
of the participants and can be an origin for recall bias. Regarding information on obstetrical 
history it is possible that women who have experienced IUFD have had more focus on and recall 
better the details of their reproductive/obstetrical history. As an example they might have a better 
memory of early miscarriages. This could result in more pathology reported by the cases, a 
systematic bias, that would in return cause an overestimation of the risk for pathology among the 
cases compared to the controls. 
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7.   Discussion of main findings
7.1   Incidence of IUFD
The incidence of IUFD in our material was 4.1/1000 deliveries. For comparison, the incidence >
28 completed gestational weeks in our material was 3.3 per 1000 (95% CI 2.9-3.6). This is in 
range with the rates reported in other Nordic countries. The rates of stillbirth > 28 weeks in 
Sweden, Finland and Denmark, were in the period 1996-2000 reported to be 3.5 per 1000 births, 
2.5 per 1000, and 4.0 per 1000, respectively [248] and in 2008 the rates were 2.7 per 1000, 2.0 
per 1000 and 2.2 per 1000, respectively [21]. According to The Norwegian Medical Birth 
Registry the mean incidence of IUFD > 23 weeks in Norway in the period 1990-2003 was 5.6 
per 1000, but there was reported a decline in the rates from 6.8 per 1000 in 1990 to 4.2 per 1000 
in 2003 [249]. We could not demonstrate this decline in incidence in our material.  Neither could 
we confirm the finding of increasing incidence of IUFD as reported from England, Wales and 
Northern Ireland in the early 2000s [250], although we found a slight, but non-significant,
increase in the incidence of stillbirth in the period 2000-2003 compared to the period 1990-
1999. The difference in the stillbirth rates in our material and that reported in Norway in general 
could be explained by variations in stillbirth rates between different areas possibly caused by 
differences in the composition of the obstetric population or by different access to medical care. 
Norway is a large country with scattered inhabitation and long distances to medical facilities in 
some areas.
The literature is consistent about the declining incidence of stillbirths from the 1960’s to 
the 1980’s, after which the rates have been fairly constant. The decrease in incidence has been 
observed for stillbirth of almost all causes, although it has been more prominent in some groups 
like intrapartum deaths and deaths caused by iso-immunisation (Rhesus incompatibility), but
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minimal in other groups, like deaths of infectious causes. In the same period there was a decrease 
in the absolute rates of unexplained stillbirths but their proportion of all stillbirths was the same 
in the 1980’s as in the 1960’s [38,47].
The obstetrical population is changing and compared to women giving birth in the 
1960s, today the mothers are more likely to be older, nulliparous, unmarried, overweight, have 
hypertension or diabetes during pregnancy and to have had previous abortions [75]. In many 
Western countries the obstetric population is also changing due to immigration and now 
comprises a larger proportion of women with a minority background. Several studies have found 
the risk of stillbirth to vary considerably according to ethnicity [76,90,91,98,100,101]. All these 
factors can influence the stillbirth rates [25].
The stillbirth rate differed between the 2 hospitals. This may be related to the level of 
care of the hospitals. OUS is a regional and referral hospital for a large catchment area. AHUS is 
a county hospital and has a slightly lower level of service regarding neonatal intensive care and 
according to protocol the most premature pregnancies (< 26 weeks) are referred to OUS. There 
was no difference in the rates between the hospitals when stillbirths before 27 weeks were 
excluded. Our results are consistent with the findings of a Swedish study on a catchment area-
based analysis of stillbirths and neonatal deaths. They found increasing ORs for mortality with 
increasing level of care of the delivery hospital [251]. Differences in the obstetric population of
the two hospitals, according to ethnicity, could also have contributed to this difference. However, 
we did not have data on ethnicity since that information is not registered in the antenatal or 
hospital records and could thus not explore that further.
7.2   Risk factors 
A recently published meta-analysis found the following factors to be the most important risk
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factors in high-income countries: maternal weight, maternal smoking, maternal age, primiparity, 
SGA, placental abruption and pre-existing maternal diabetes or hypertension, some of them 
potentially modifiable [34]. The factors that contributed most to the stillbirth risk at a population 
level, the population attributable risk (PAR), were found to be SGA <10th centile (PAR 23.3%), 
placental abruption (PAR 15.2%) and primiparity (PAR 14.3-15.3%) [34].
Maternal age
In our material advanced maternal age was a significant risk factor for stillbirth in the 
multivariate analysis, when compared with facility-based controls. Most studies in the last two 
decades, both facility- and population-based, report advanced maternal age, in a variable 
magnitude, to be a risk factor for stillbirth [23,49,75-78,81,90]. A recent meta-analysis of 
Flenady et al. found maternal age of more than 35 years to be associated with a 65% increase in 
the odds of stillbirth (OR 1.65, 95% CI 1.61-1.71), but increasing with age over 40 (OR 2.29; 
95% CI 1.54-3.41) [34]. One proposed explanation is failure of the uterine vasculature in older 
women to adapt sufficiently to the increased hemodynamic demands of pregnancy [104].
Authors who have studied the association between fetal growth restriction, advanced maternal 
age and stillbirth do not agree with this theory, since stillborn fetuses of older women have not 
been found to be more growth restricted than fetuses of younger women [48,252]. The maternal 
age-related risk of stillbirth is important since the obstetrical population is changing in developed 
countries and the number of births to women 35 years and older is increasing.
Parity
We did not find the risk of stillbirth to differ by parity in the multivariate analysis. Some reports 
have shown increased risk among multiparous (> 3 births) and/ or nulliparous women [75,77,78].
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Smoking
Smoking was an independent, significant risk factor for IUFD. When smoking was added to the 
statistical model, being single (neither married nor cohabiting) was no longer a significant risk 
factor for IUFD. This was in concordance with single women more often being smokers. The 
association between smoking and fetal death has been documented in several studies and 
placental pathology is suggested as a proposed pathway [24,78]. A recent meta-analysis of 
studies in high-income countries found a 36% increased odds of stillbirth associated with 
smoking (OR 1.36; 95% CI 1.27-1.46) and PAR of 4-7%, but higher in groups where smoking 
was more prevalent [34]. Raymond et al. demonstrated that in pregnancies of smoking women,
with no known placental pathology/complications, there was not an increased risk of stillbirth 
[78]. They found this by excluding from analysis women with IUGR, placental abruption or 
placenta previa. Our results do not quite agree with this as we found smoking to be a risk factor 
of equal size in all causal groups as described in Paper IV. Other authors have documented an 
association between smoking and IUGR, where smoking more than 10 cigarettes per day was a 
strong risk factor for unexplained stillbirths among cases with IUGR [48]. We assessed the risk 
associated with smoking by smoking habits reported at first antenatal visit. Studies suggest that 
women who reduce or quit smoking in the first trimester have a comparable risk of stillbirth as 
non-smokers [253]. This emphasizes the importance of awareness of the risk associated with 
smoking and anti-smoking campaigns in early pregnancy.
Gestational age
The conditional probability for IUFD in our material was unchanged through weeks 24–35, 
thereafter increasing continuously with advancing gestational age. Similar results have been 
reported elsewhere, even though the rate of stillbirths per 1000 deliveries decreases with 
advanced gestational age [57,77,78,115]. The trend in our material is consistent with a Scottish 
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study which examined the estimated probabilities of stillbirth from 37 gestational weeks and 
onward [114]. But despite this trend of progressive stillbirth risk we did not find the risk in 
gestational weeks 41 or 42 weeks to be significantly greater than the risk in week 40. Other 
authors have described similar findings [55,78]. The gestational-age related risk of stillbirth has 
been found to increase with advanced maternal age [77,78] and Hilder et al. observed that the 
risk for IUFD in post-term pregnancies was more evident among nulliparous women, particularly 
after 42 weeks [254].
Twin pregnancies
Twin pregnancies, especially of monozygotic twins, are characterized by an increased incidence 
of fetal and maternal complications often related to placental pathologies, both common 
complications like hypertensive disorders, placental abruption and IUGR and complications 
unique to twin pregnancies as twin-twin transfusion syndrome [36,255].
Placental abruption
We found the OR of the association of placental abruption and IUFD to be 15.4-22.0. Placental 
abruption is a leading cause of stillbirth, and reported to cause 15% of stillbirths in a recent 
analysis of causes of stillbirth in high-income countries [27], which was in agreement with our 
results of 16%. However placental abruption does not always cause stillbirth, although abruption 
involving 50% or more of the placenta frequently does [126]. A recent analysis reported the PAR 
of stillbirth related to placental abruption to be 15%, despite the low prevalence of abruption 
[34]. It appears that, in the vast majority of cases, abruption is the end result of a chronic process,
a consequence of pathological placentation [126].
SGA
We identified a greatly increased risk of IUFD related to SGA, and the risk related to 
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hypertensive disorders was mediated through SGA. Fetal growth restriction is reported to be the 
single largest category of conditions associated with IUFD (43%) [50,53]. Rather than being a 
diagnosis unto itself, SGA is a sign of a variety of other conditions that may lead to fetal death. 
Our result of SGA being almost equally prevalent in all the causal groups is a confirmation of 
that. Poor fetal growth, without other environmental causes, is assumed to indicate poor function 
of the placenta, but whether IUGR is a marker of placental insufficiency or causally associated 
with the mechanism of death is unclear [38]. SGA is also associated with congenital 
malformations and multiple pregnancies. Frequently though, none of these conditions are present 
in SGA pregnancies, as can be reflected by the large proportion of SGA-fetuses reported among 
unexplained IUFDs [48]. In prevention of stillbirth the correct diagnosis of IUGR is of great 
importance. In Northern Ireland, in the Confidential Inquiry into Stillbirth and Infant Death, it 
was concluded with that the most common error in antenatal care was failure to adequately 
diagnose and manage fetal growth restriction [224]. Evidence is lacking for the benefit of 
antenatal testing, although theoretically some methods could be adequate, like fundal height 
measurements [256], customized growth charts [257] and counting of fetal movements [258].
Doppler ultrasonography of the umbilical arteries has been demonstrated beneficial in reducing 
stillbirths among women in high-risk pregnancies with preeclampsia and suspected IUGR [259]
and assessment of fetal growth by ultrasound has been demonstrated to improve outcomes in 
IUGR pregnancies [225].
Hypertensive disorders
In our material, women with isolated hypertension (HT) had a greater risk of stillbirth than 
women with established preeclampsia (PE) and in fact when the cases were compared with the 
selected controls PE was not associated with stillbirth, unless in combination with SGA. We 
found that the major risk of IUFD associated with hypertensive disorders (HD) was mediated
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through SGA. HD without SGA were only mildly associated with IUFD. This might be 
explained by HD and SGA being a symptom of the same condition, placenta insufficiency, with
SGA representing a more serious form [126].
The difference in the risk of stillbirth associated with HT and PE can possibly be 
explained by that women with PE get better surveillance and induction of labor, when indicated, 
even in the preterm period, thus avoiding stillbirth, while women with HT only do not get 
adequate attention. In one study where the authors found chronic hypertension, but not 
gestational hypertension, to be associated with stillbirth it was presumed that the women with 
gestational hypertension recieved better surveillance and earlier delivery when indicated [133].
The pathogenesis of pregnancy related HD is assumed to be through placental pathology 
[131], therefore it was not unexpected to find HT as a risk factor in the group of placental causes
of death. But HT was also found to be a risk factor in the group of unknown causes which could 
be explained by insufficient information to place them in the category of placental causes or that 
the placenta pathologies detected were subtle and not regarded as the major cause of death.
Other authors have reported either no [47,90] or a very modest association between 
hypertension and stillbirth [75,76,90], but comparison across studies is difficult because SGA is 
usually not adjusted for [76]. A recent report found pre-existing hypertension associated with a 
2.6 times increase in the odds of stillbirth with PAR of 7-14% [34]. Preeclampsia was found to 
be associated with a more moderate risk, but still a 60% increase in the risk of stillbirth, with 
PAR of 3% because of the low prevalence [34].
Diabetes mellitus
We found women with diabetes (pre-gestational and gestational) to have a three- to five-fold risk 
of stillbirth. This is in agreement with several other studies [81,146,148]. Stephansson et al. 
reported in a Swedish population a 14-fold increased risk of stillbirth associated with diabetes 
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mellitus but no association with gestational diabetes [81] and a British study found 5-fold 
increased rates of antepartum stillbirths among women with diabetes type 1 or 2 [148]. A recent 
meta-analysis also concluded with an association between pre-existing (OR 2.9; 95% CI 2.05-
4.09), but not gestational diabetes [34]. Pre-existing diabetes mellitus is still one of the maternal 
medical disorders most strongly associated with stillbirth, although it does not contribute much 
to stillbirth risk at a population level (PAR 3-5%) [34]. However, reports from referral centers 
suggest that with optimal management the risk of perinatal death associated with diabetes is only 
marginally above that of the general population [75].
Diabetes was a significant risk factor for stillbirths of placental and unknown COD, but 
the OR in the unknown group was double that of the placenta group. The exact mechanism of 
fetal death in diabetes mellitus is unknown, but alterations in fetal carbohydrate metabolism and 
uteroplacental insufficiency secondary to vascular disease are possible explanations [260].
In 1999 women of non-Western origin comprised approximately 25% of the pregnant 
population in Oslo, the largest group from Pakistan [261]. These women have higher rates of 
diabetes as well as stillbirth [101,148]. One can speculate that some of the risk attributed to 
diabetes in our material actually relates to ethnicity, but since we did not have information on 
ethnicity, we could not correct for that in the multivariate analysis. However, a Swedish study 
found diabetes a significant risk factor for perinatal mortality even when adjusting for maternal 
origin [262].
Thyroid disorders
We found thyroid disorders to be associated with stillbirth. Both hypo- and hyperthyroidism are 
reported to be associated with an increased risk of IUFD [46]. Fetal thyrotoxicosis may be the 
cause of death in some instances [263] and a two-fold increase in the risk of stillbirth is reported 
for women with hypothyroidism [264]. Hypothyroidism appears to be associated with increased 
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risk of hypertensive disorders [265]. Adequate thyroxin replacement improves the likelihood of a 
successful pregnancy.
There are few reports comparing risk factors according to cause. Frøen et al. evaluated 
risk factors among women with unexplained and explained stillbirths. The only significant 
difference he found was that women with explained stillbirth had more often glycosuria [1]. But 
he did also investigate variations in risk factors for unexplained fetal death in pregnancies with 
and without IUGR and found that among women with IUGR-pregnancies smoking, maternal 
overweight and low education were associated with unexplained stillbirth, while in pregnancies 
without IUGR, smoking was not a risk factor, but maternal age >35, overweight, and low level of 
education were [48].
7.3     Thrombophilic risk factors
Different pathways of the pathogenesis of thrombophilia associated pregnancy complications are 
constantly being investigated. Accumulating data are suggesting that an abnormal or exaggerated 
hemostatic response to pregnancy might be a potential cause. Several studies have demonstrated 
that some women with recurrent pregnancy loss are in a prothrombotic state when non-pregnant 
[266] suggesting that the further hypercoagulable state of pregnancy places them at risk of fetal 
loss and even a systematic thrombotic event. But other mechanisms of pathogenesis are being 
proposed and investigated. There are reports of that women with recurrent pregnancy loss are in 
a chronic state of endothelial stimulation associated with activation of the coagulation system 
[267]. Elevated levels of circulating procoagulant microparticles have also been described in the 
circulation of women with both early and late miscarriages, directly affecting the coagulation 
cascade in addition to possible pro-inflammatory and/or pro-apoptotic action disturbing
successful implantation and subsequent fetal growth [268].
 96 
 
Few studies investigating the association of thrombophilia and stillbirth consider the 
influence of confounders. Kist et al. investigated the effect of confounders in a meta-analysis 
[269] and found the association of FVLeiden and several pregnancy complications to be 
confounded by ethnicity, genetic testing only and severity of disease. As an example, they found 
the association between FVLeiden and IUFD to be stronger in 2nd and 3rd trimester fetal losses 
rather than in 1st trimester recurrent fetal loss.
7.3.1   Inherited thrombophilia     
Factor V Leiden 
We did not find a significant association between FVLeiden and stillbirth in general, but the 
prevalence was double among women with placental or unknown COD compared to the controls, 
although this did not reach statistical significance, probably due to small sample size. This 
finding could support a placental nature of the association. Case-control studies have variably 
demonstrated this association. A meta-analysis of prospective cohort studies in 2010 reported on 
PMPC [270]. Seven studies investigating the association of FVLeiden and pregnancy loss in all 
trimesters were included. For the association of FVLeiden and pregnancy loss they found a pooled 
OR of 1.52 (95% CI 1.06-2.19), but there were important inconsistencies in the definition of the 
outcomes and statistical heterogeneity across studies. When two studies including either 
spontaneous abortions or stillbirths only were excluded the association between FVLeiden and 
pregnancy loss was not significant (OR 1.34; 95% CI 0.9-1.98).  Said et al. in his prospective 
study did find a positive association, but only six cases of stillbirth after 22 weeks were included 
in the study [271]. Meta-analyses including case-control studies have concluded with a mild to 
moderate association between FVLeiden and IUFD with ORs in the range 2.06-3.26 [5,6,272]. The 
included studies addressed IUFD after 20-27 weeks, but were of small sample size, comprising 
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3-67 cases, apart from one study that involved 232 cases [8]. Meta-analyses have concluded with 
that the association between FVLeiden and IUFD is stronger for women with more than one fetal 
loss [272] and when the fetal losses occur later in pregnancy [6,272]. More recently published
case-control studies, not included in the meta-analyses, have not found FVLeiden to be a risk 
factor for IUFD [4,273]. Gonen et al. studied 37 women with stillbirths in gestational weeks 27-
42 [4] and Pasquier et al. 58 women with unexplained pregnancy loss after 21 gestational weeks 
[4]. The divergent results across individual studies reporting on the association of FVLeiden and 
IUFD are probably caused by differences in study design, selection of cases and controls, 
definition of the gestational age at the time of IUFD, and sample size [274].
The prothrombin gene polymorphism
We found the prothrombin polymorphism to be significantly more prevalent among women with 
a history of IUFD compared to women with live births only. This association seems to be more 
consistently reported in the literature than the association of FVLeiden and stillbirth. A meta-
analysis of case-control studies and several review articles have reported an association between 
the prothrombin polymorphism and late fetal loss with ORs in the range of 2.3-3.3 [6,157,275].
There are few prospective studies, with small sample sizes, that report on the association. Said et 
al. reported on 6 cases of IUFD after 20 gestational weeks in a cohort of 1707 women and did 
not find a significant association (OR 8.31; 95% CI 0.9-73) [271]. A meta-analysis of 
prospective cohort studies did not find an association between prothrombin polymorphism and 
pregnancy loss, but the sample size was found to be insufficient to detect important risk 
associations [270].
The finding of the prothrombin polymorphism to be significantly associated with 
stillbirths of placental causes would be expected since the main pathogenesis of stillbirth related 
to thrombophilia is assumed to be mediated through abnormalities in placental vasculature [186].
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But even though a significant association was only found in the group of placental causes, the 
prevalence of the prothrombin polymorphism was similar in the group of other causes (8.2% and 
6.1% respectively compared to 1.5% in the control group). Korteweg et al. did not find 
significant differences in the prevalence of thrombophilic defects when comparing women with a 
placental cause with women with a non-placental cause of stillbirth, but they did not compare
women with different causes of stillbirth with live-birth controls [62].
Antithrombin, Protein C- and protein S deficiency
We did not find AT, PC- or PS deficiencies to be significantly associated with stillbirth. The 
reported associations of these deficiencies with IUFD are conflicting, which probably reflects the 
low prevalence of these conditions and thus the small numbers of deficient women investigated
[6], which applies to our study as well. Thus most studies, including our study have not had 
sufficient power to demonstrate these associations. PS deficiency is usually found to be 
associated with IUFD, with high ORs, but not always significant because of few cases studied. A
systematic review has demonstrated a significant OR of 20.1 (95% CI 3.7-109.2) based on 2 
studies [6]. Korteweg et al. demonstrated recently that women with IUFD more often had 
significantly decreased levels of AT and PC during pregnancy compared with healthy pregnant 
women, although the levels remained within the normal range for non-pregnant women [276].
There is still great uncertainty regarding the association of inherited thrombophilia and stillbirth.
But despite an increased relative risk of stillbirths and other adverse pregnancy outcomes (APO) 
associated with inherited thrombophilia, the absolute risk would remain modest because of the 
low prevalence of thrombophilias and the relatively low incidence of APO. The Risk and 
Economic Assessment of Thrombophilia Screening (TREATS) study [6] reviewed all
prospective and retrospective studies concerning the association between thrombophilia and 
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venous thrombotic events (VTE) or APO and concluded with that universal thrombophilia 
screening among pregnant women was not supported by evidence. The study found selective 
screening based on previous VTE history to be more cost-effective. As long as there is 
uncertainty about the association between thrombophilia and stillbirth and while no good 
placebo-controlled intervention studies are available, prophylactic measures are to be thought of 
as experimental. A large placebo-controlled trial is being conducted at the moment, comparing 
low molecular weight heparin and placebo (saline) among pregnant thrombophilic women with a 
history of PMPC (http://clinicaltrials.gov/ct2/show/NCT00967382). Randomized controlled 
trials have been conducted among women with recurrent miscarriage of unknown origin and the 
use of anticoagulant therapy has not been proved beneficial [277,278].
7.3.2   Antiphospholipid antibodies
In the present study, we found that women with a history of IUFD, as compared with women 
with live births only, were significantly more often positive for LA 3-18 years after the index 
pregnancy. The association was confined to women positive for LA in combination with other 
APAs. There is evidence that the presence of multiple APAs may increase the risk of thrombosis 
and severe pregnancy complications [279]. Therefore, patients with antiphospholipid antibody 
syndrome (APS) with multiple APA positivity are considered at higher risk for recurrence. Our
study implies that multiple positivity is important, although firm conclusions cannot be made,
due to the nature of the study and small sample size. Our results are in agreement with other 
recent studies that have demonstrated multiple positivity for APAs to be more frequently 
associated with pregnancy complications than single positivity [280,281].
We cannot exclude the possibility that some women have either turned negative or turned
positive for APAs after the index pregnancy, but there is no reason to believe this to differ
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between cases and controls. Remarkably little is known about the sustainability of APAs over 
time and we know of no studies that have investigated this among women with a history of 
IUFD. In one study, Erkan et al. found sustained positivity over time for approximately 75% of 
tests initially positive, but with a mean follow-up time of only 2.4, 3.5 and 1.0 years for LA, 
aCL, and anti-2 GP1, respectively [282].
Although there is possibly some increased relative risk of IUFD associated with APAs, 
the absolute risk for APA positive women without previous clinical events is low, and the 
probability of a successful pregnancy outcome is high. Thus, the screening for APAs in an 
unselected population of pregnant women is not recommended. The 8th Guidelines on 
Antithrombotic Therapy of the American College of Chest Physicians (ACCP) from 2008 
recommend screening for APAs among women with a history of PMPC [195]. Low molecular 
weight heparin and low dose acetylsalicylic acid are currently only recommended for the 
prevention of recurrent pregnancy loss in women with APAs [195,232-234].
7.4     Thrombophilia and placenta pathology
Thrombotic lesions of the placenta are a common finding among women with stillbirth [283], as 
with other PMPC [186]. Of importance concerning the relationship between thrombophilia and 
placental pathology is whether coagulation abnormalities are underlying causes of abnormal 
placentation or adversely affect an already compromised placenta. No placental lesions have 
been demonstrated to be unique or specific for coagulopathy and the placental pathology for 
PMPC like IUGR, PE, placental abruption and stillbirth are very similar in patients with and 
without underlying maternal thrombophilia [190,284,285]. Abnormal uterine artery Doppler is in 
fact more predictive of villous infarcts and intervillous thrombosis than maternal thrombophilic 
disorders [286]. Studies have suggested that complications in late pregnancy may be determined 
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by impaired placental function already in the first 10 weeks after conception [122]. Presumably 
defective spiral artery transformation renders these vessels prone to thrombosis. Similar findings 
at delivery might simply represent a final common pathway for different underlying 
abnormalities. 
7.5     Classification
In the present study we found over half of all stillbirths to be caused by or associated with 
placental pathology (68.4%). A report from the Netherlands regarding classification of perinatal 
deaths by Korteweg et al. found 2/3 of the deaths to be caused by placental pathology, classified 
according to the Tulip classification [53,276]. They stated that classification systems without a
group of placental causes or with only a minimal subdivision of this group were not useful in 
modern perinatal audit as loss of information would occur. Another recent analysis of perinatal 
deaths in high-income countries demonstrated that placental pathologies were causal or 
contributory in more than half of stillbirths [27]. Other reports have also found placental causes 
in up to 60% of the cases [69,72,287]. Rayburn et al. reported already in 1985 that most 
intrauterine deaths in the 3rd trimester were due to placental dysfunction, chronic or acute [287].
The risk of death in pregnancies with dysmature placenta has been shown to be 70-fold 
that of pregnancies with a normal placenta [288]. Placental dysfunction can be divided into 
chronic or acute dysfunction [288]. Early diagnosis of placental dysfunction is a major clinical 
challenge. For chronic dysfunction it is possible to detect IUGR, as the fetus does not grow 
according to its growth potential. No such markers are available for acute placental dysfunction.
Placental histological examination has received increasing attention in determining the 
causes of stillbirths as the findings can support or contradict the suggested diagnosis, or provide 
new clues [287,289] as has been pointed out by others [51,53,72]. Other main sources of 
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information in stillbirth investigation are the maternal and fetal health and history and the 
autopsy [51]. Availability of placental histological examination is reported to generate higher 
rates of stillbirths with placental causes and reduction in unexplained stillbirths [51,53]. But 
causality related to placental pathology can be unclear and avoiding over-interpretation of 
placental findings is thus important [255,290].
However, although placental failure is becoming a more recognized cause of 
stillbirth many classification systems do not address placental cause of stillbirth. Such 
classifications generate an excessive number of unexplained deaths otherwise allocated a 
placental cause in other classifications [53]. Newer systems like CODAC or the Tulip 
classification do recognize this group [60,62,69].   
We reported 20% of IUFDs in our material with an unknown cause. A recent report of 
causes of stillbirth in 6 high-income countries, classified according to CODAC, reported 30% of 
the cases with an unknown cause and found the main reason for this a failure to perform
adequate investigations as only 5% of stillbirths that underwent full assessment were 
unexplained [27]. The reported numbers of unexplained stillbirth in the literature ranges from 9 
– 71% [49-51]. The proportion of unexplained stillbirths is dependent on both the sources of 
information available in addition to the classification system used. Classification systems capable 
of retaining important and detailed information have a lower proportion of unexplained deaths 
[62,69]. In a comparison with 5 other classification systems CODAC recieved the highest score 
regarding the ability to retain important information and for the ease of use. It had the lowest 
proportion of unexplained stillbirths and a fair inter-observer agreement [51].
The proportion of our cases distributed in the other causal groups was in agreement with 
recent reports by Flenady et al. [27] and Goldenberg et al. [42].  
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8.     Conclusions
The incidence of IUFD was 4.1/1000 deliveries. Classified by the CODAC-classification half of 
all stillbirths had placental causes and 20% had an unknown cause that had placental associated 
conditions in 35.6% of the cases. SGA and placental abruption were found to be the strongest 
risk factors for IUFD. The risk of HD was mediated through SGA, and no or moderate risk was 
associated with HD if not accompanied by SGA. Other risk factors detected were, pre-pregnancy 
and gestational DM, thyroid disease, placenta previa, twin pregnancy, smoking, and advanced 
maternal age. These were of low prevalence and associated with low or moderate ORs and 
therefore probably of limited importance in further reducing the rates of stillbirths, although 
important in the prevention of IUFD in general. Smoking and SGA were significant risk factors 
across all causal groups. Women with IUFD of placental or unknown causes had many risk 
factors in common; twin pregnancy, hypertension and diabetes, which were not risk factors for 
IUFD of other causes. The risk estimates pointed in the same direction regardless of the control 
group, even though the absolute risk estimates were slightly different using different control 
groups.
Women with a history of IUFD after 22 gestational weeks were more often LA positive, 
3-18 years after the incident, but the association seemed to be confined to women positive for 
other APAs in addition to LA. APAs as a composite variable were found to be associated with 
IUFD of other causes (than placental or unknown). There is however still great uncertainty 
related to the association of APAs and IUFD and the clinical importance is not easily predicated. 
The prothrombin polymorphism was significantly associated with IUFD compared to 
women with live births only, but not FVLeiden or AT-, PC-, or PS deficiencies. When analyzed in 
separate causal groups the prothrombin polymorphism was a significant risk factor only among 
women with stillbirth of placental causes. 
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Stillbirth is a multifactorial disease including genetic, acquired and environmental 
determinants, which may interact on various levels. Many stillbirths in high-income countries are 
potentially preventable and preventive strategies that target risk factors are important in rate 
reduction. Prevention of stillbirths caused by placental insufficiency is dependent on the 
detection of women at risk and appropriate timing of birth, although planned early delivery needs 
to be weighed against the risk associated with intervening at a given gestational age. IUGR can 
be a sign of placental insufficiency, especially chronic placental dysfunction, and is the risk 
factor most frequently associated with stillbirth, thus the correct diagnosis of IUGR is of great 
importance. However, early diagnosis of placental dysfunction and IUGR are a major clinical 
challenge and no markers are available for acute placental dysfunction [288]. Screening of low-
risk women has been demonstrated non-beneficial in detecting women at risk for complications 
like PE and/or IUGR [291,292]. A group of investigators has proposed the use of a “placental
profile” as screening for the likelihood of PE, IUGR, placental abruption or IUFD among high 
risk women with medical and/or previous obstetric complications. They conducted a study 
estimating placental profile by 3 separate tests; maternal serum screening, second trimester 
uterine artery Doppler imaging, and placental morphologic condition. Women with all tests 
normal had significantly decreased risk of adverse pregnancy outcomes. If this profiling would 
accurately identify the subset of women at greatest risk for complications, this could be of
advantage to both the patient and her physician, by providing reassurance to women with normal 
test results, and providing sufficient follow-up to the women at greatest risk for complications 
[293].
Recognition of the risks associated with medical disorders like diabetes and hypertension 
and implementation of guidelines that might improve management is of importance. Not all risk 
factors are avoidable, as for an example advanced maternal age. But awareness of the risks 
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attributed to such factors is important in choosing the appropriate follow-up regimen for these 
women. Theoretically awareness regarding the risk associated with advanced maternal age might 
also affect the women’s choice of delaying childbearing. 
Despite some increased relative risk of IUFD associated with thrombophilia, the absolute 
risk is low and thus the probability of a successful pregnancy outcome among women with 
thrombophilia high. There is no evidence to support universal screening of thrombophilia among 
pregnant women [294]. The 2008 guidelines from the American College of Chest Physicians
(ACCP) on antithrombotic therapy and pregnancy recommend women with PMPC to be 
screened only for antiphospholipid antibodies (APAs), with a further investigation only if APAs
are negative [195].
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9.     Future perspectives
Further research is needed regarding appropriate measures to detect women/ pregnancies at risk 
for stillbirth, especially those at risk for placental dysfunction, which is a major contributor to 
stillbirth in high-income countries. The benefit of the interventions and cost-effective analysis, as 
on serial ultrasound examination for the detection of IUGR, should be investigated.
Benefit of other preventive strategies needs to be confirmed in studies, like weight 
management, efficacy of smoking cessation programs, improvements in antenatal care, use of 
interpreter in case of language barrier and risk reduction associated with induction of labor at 
different gestational ages.
Better understanding of the pathogenesis of IUFD among women with inheritable or 
acquired thrombophilia is needed in order to develop treatment options. It is possible that some 
still unknown thrombophilias could be involved in the pathogenesis of stillbirth. Recently low 
levels of protein Z [295,296] and reduced expression of annexin A5 [297,298], natural 
anticoagulant proteins, has been suggested to be associated with adverse pregnancy outcomes. 
This needs further investigation. 
A large proportion of stillbirths are of placental causes. Further research regarding 
identification of clinical manifestations of placental pathology as well as focus on screening and 
interventions is important for the prevention of these deaths.
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Précis
Classification of stillbirths by the Cause Of Death and Associated Conditions (CODAC) 
classification system and socio-demographic, clinical and thrombophilic risk factors by cause.
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Abstract
OBJECTIVES: To classify stillbirths applying the Causes of Death and Associated Conditions
(CODAC) - classification system and to investigate risk factors by cause.
METHODS: Observational case-control study of 377 women with stillbirths after 22 gestational 
weeks, and 1 215 controls with live births at two University hospitals in Oslo, Norway during 
1990-2003. The stillbirths were classified according to CODAC based on relevant information 
from medical records and validated placenta histology. Socio-demographic, clinical and 
thrombophilic risk factors were estimated by causal groups.
RESULTS: A total of 190 (50.4%) women had placental and 73 (19.4%) unknown causes of 
stillbirth. In addition 68 (18%) cases with a non-placental or an unknown cause had placental 
associated conditions. Smoking and small for gestational age (SGS) were significant risk factors 
in all causal groups, while twin pregnancy, hypertension and diabetes were risk factors only for 
placental and unknown causes of stillbirth. Inherited thrombophilia combined and the F2 
rs179963 polymorphism alone were significant risk factors for stillbirth of placental causes and 
antiphospholipid antibodies for stillbirth of other causes.
CONCLUSIONS: Over half of all stillbirths (68%) were caused by or associated with placental 
pathology. Risk factors differed somewhat according to cause, apart from smoking and SGA that 
were significant risk factors across all causal groups. Similar risk factors were detected among 
women with placental and unknown causes of stillbirth.
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INTRODUCTION
Classification of stillbirths is needed for the purpose of prevention, counselling and comparison 
of health care. Assigning a single cause of death can be challenging because of interaction 
between pathophysiological processes in the mother, placenta and fetus. Ideally classification 
systems for stillbirths should be able to capture both the direct cause of death and other clinical 
entities, as this can be important for deeper insight into the etiology. Suboptimal classification 
systems may lead to loss of information and a higher proportion of unexplained deaths. No single 
system is universally accepted, and this impedes comparison of stillbirth data. Data on risk 
factors by cause are limited.
The CODAC (Causes of Death and Associated Conditions) classification system for 
perinatal death is designed to retain information on the main cause of death as well as up to two 
associated conditions (1).  It was developed by an international  collaboration and has recently 
been evaluated and compared with 5 other classification systems (2). CODAC received the 
highest score regarding the ability to retain important information and for the ease of use. It had 
the lowest proportion of unexplained stillbirths and good inter-observer agreement (2).
Placental histology can support or contradict suggested diagnoses, or provide new clues 
and has received increasing attention in determining the cause of stillbirth. Many classification 
systems do not include placental causes of stillbirths, although most new classifications do 
(1,3,4). The aims of this study were to classify stillbirths according to CODAC and to study the 
association of risk factors by causal groups.
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MATERIAL AND METHODS
The present study was a part of a larger hospital-based case-control study; the Venous 
Thromboembolism In Pregnancy (VIP) study, and was registered as a clinical observational 
study at www.clinicaltrials.gov, with registration number NCT00856076 (5,6). Data on 
epidemiological, clinical (7) and biochemical risk factors for stillbirth (8,9) have been published. 
All women with a diagnosis of stillbirth, from January 1st 1990 through December 31st
2003, at Oslo University Hospital Ullevål (OUH), Oslo, and Akershus University Hospital 
(AHUS), Nordbyhagen, both Norway, were identified retrospectively by a search for selected 
codes of the WHO International Classification of Diseases (ICD) versions 9 or 10, using the 
patient administrative system of the respective hospital. We identified 434 possible cases of 
stillbirth, defined as intrauterine fetal death in singleton or duplex pregnancies after 22 
completed gestational weeks or birthweight > 500 g. After reviewing the medical records, we 
excluded 49 cases wrongly diagnosed and eight with non-retrievable records, leaving 377 
women with a verified diagnosis of stillbirth. The expected date of delivery was estimated by 
routine ultrasound examination at 16 to 18 gestational weeks for 73% of the women. In the 
absence of ultrasound data, gestational age was determined by the first day of the last menstrual 
period. The time of fetal death was determined by the gestational age at diagnosis. 1 229 women 
delivering at OUH in the study period were selected for the control group. After exclusion of 5 
women under the age of 16 or over 44 years (none of the cases were in these age groups) and 9 
women with  stillbirth, the control group comprised 1 215 women with live singleton or duplex 
births at OUH in the study period.   
The cases and controls were identified at the participating hospitals, medical records 
retrieved, and reviewed for validation of the diagnosis of stillbirth and other relevant 
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information. Individual data were transferred to a case-report-form which comprised data on 
demographics, general health, obstetrical history, details of the index pregnancy and delivery, 
post-mortem examination of the infant, and laboratory data including histological examination of 
the placenta. The case-report-forms were scanned, consistency analysis run and invalid data 
entries corrected after a review of relevant medical records. Risk factors assessed were maternal 
age, parity, marital status, assisted reproductive therapy, smoking habits, twin pregnancy, thyroid 
disease, pre-existing diabetes mellitus, gestational diabetes, hypertensive disorders, small-for-
gestational-age (SGA), placental abruption and placenta previa. Validated population-based 
growth charts were used to determine whether the fetus was SGA, which was defined as 
birthweight below the 2.5th percentile for gestational age.
In 2006-2008 the cases and controls were invited to participate in the study to answer a 
questionnaire and to donate a blood sample. Women, who had emigrated, were foreign citizens, 
dead or had an invalid or unknown address, were excluded, and two additional cases had been 
identified. A letter of invitation was received by 346 cases of which 105 agreed to participate. 
The controls received first an invitation to participate in the thrombosis part of the VIP study 
(10,11), in which 353 agreed to participate. After exclusions, including 9 women with a history 
of stillbirth, 326 controls with live births received an invitation for this part of the VIP-study, and 
262 agreed to participate (Figure 1).
Lupus anticoagulant (LA) was analysed with validated in-house lupus ratio tests (12),
based on both activated partial thromboplastin time and Russell’s viper venom time. 
Anticardiolipin (aCL) IgM and IgG antibodies were analysed with in-house ELISA tests and 
anti-2 glycoprotein 1 (anti-2GP1) IgG and IgM antibodies with commercial ELISA kits 
(QUANTALiteTM 2GP1, INOVA Diagnostics Inc., San Diego, USA). The cut-off values for a 
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positive test were defined by the 99th percentile of the values of the control group. Antithrombin 
and protein C activities and free protein S were determined using commercial kits from 
Instrumentation Laboratory Inc, Bedford, MA, USA (Coamatic® Antithrombin, Coamatic® 
Protein C and HemosILTM Free Protein S reagent kits, respectively). Women with Antithrombin
activity < 80%, Protein C activity < 70% and Protein S two standard deviations below the mean 
of the controls were defined as deficient. The F5 rs6025 (factor V Leiden) and the F2 rs179963
(prothrombin gene G20210A) polymorphisms were detected with commercial detection kits 
(Roche Diagnostics, Basel, Switzerland). Two women reported use of warfarin medication at 
time of blood sampling and were therefore excluded from analyses of inherited thrombophilia.
The results of the original histological examinations of the placentas were reviewed. The 
placentas had originally been evaluated by general pathologists, but no standardized protocols 
for macro- and microscopic evaluation or sampling of placental tissue were in use in the study 
period. In most cases sections had been sampled from the umbilical cord, the membranes and 
minimum two sections from placental tissue from areas with and without focal parenchymal 
pathology. The tissue sections had routinely been fixed in formalin, processed and embedded in 
paraffin blocks, and 3.5 μm sections stained with Hematoxylin-Eosin.  
For the purpose of a more accurate classification of causality, the original placenta 
specimens were retrieved and reassessed, when available. Placental tissue from 268 stillbirths
were reassessed by two experienced pathologists (G.T. and B.R.) with special interest in 
placental pathology, blinded to the clinical details of the stillbirth. Cases with microscopic signs 
of acute or chronic villitis and/or intervillositis were immunostained with a standard panel of 
antibodies to T-cell- and histiocytic markers. When the placenta specimens were not available 
for reassessment the original histological descriptions (n=99) were used. Histological 
 Helgadottir
8 
 
descriptions of the placenta were available for 367/377 (97.3%) of the cases. Placenta 
information from controls was very limited because histological examination of the placenta is 
rarely carried out among normal birth giving women.
CODAC is a classification system for perinatal deaths, recently developed by an 
international collaborative group of investigators (1). In order to classify the case in CODAC, 
only minimum of information is mandatory but more detailed information usually generates a 
more accurate classification. The main focus is the “cause of death” (COD), with the possibility 
of coding for two additional “associated conditions” (ACs) to obtain more detailed information. 
For each case, CODAC thus allows up to three codes with three digits each (123 123 123), 
although only one code (123) is necessary. The first (or single) code represents the main COD. 
The second code can represent a secondary COD (if the first is not thought to be sufficient to 
fulfill the criteria of a solitary COD) or an AC, and the third code represents an AC. The first 
digit in each code represents “Level I” or the main categories of the COD or the AC (Digital 
supplement tables 1 and 2).  The second and third digits, in each code, represent Levels II and 
III, each level representing more detailed information. Each Level I category are comprised of 
several Level II categories which in turn are comprised of several Level III categories. Ten 
coding rules have been defined for CODAC (1). To be a COD the condition should be expected 
to be mortal in a significant proportion of cases (5%) and to be an AC the condition should 
contribute significantly in explaining the circumstances of death. The system includes ten main 
groups (Level I), 94 sub-groups (Level II) and 577 sub-sub-groups (Level III). Two of the main 
groups were not relevant for coding in this study (group 9: termination and group 1: neonatal 
death). When all available information on each case had been reviewed it was assigned the most 
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appropriate code(s) according to the CODAC classification system by one of the authors 
(L.B.H.).
For detection of potential variations in risk factors according to cause, risk factors were 
analysed by comparing prevalences in different causal groups with prevalences in the control 
group. The eight actual main causal groups were analysed in three groups: placental causes 
(N=190), unknown causes (N=73) and other causes (the remaining six causal groups combined 
in one) (N=114). Risk factors were analysed by chi-squared tests or Fisher’s exact tests and 
multiple logistic regression analysis. Missing values for sociodemographic and clinical variables 
were denoted the reference group. Variables included in the multivariate models were chosen 
based on the significance of each variable in the univariate analyses (p-value <0.15). The results
are presented as percentages, odds’ ratios (OR) and adjusted ORs (aOR) with 95% confidence 
intervals (CI). Significance level was set at p<0.05. Interactions between significant factors were 
tested at a 95% significance level (p<0.05). All data was analyzed using the Statistical Package 
for Social Science version 16.0 (SPSS Inc, Chicago, Il, USA).
The Regional Committee for Medical Research Ethics, Region East, Norway, approved 
the study. Authorization for the use of information from medical records for research purposes 
was obtained from the Norwegian Ministry of Health and Social Affairs. The Norwegian Data 
Inspectorate approved the use of data comprising sensitive personal health information, and the 
merging of clinical and register-data by using the unique 11-digit personal identification number 
given to all Norwegian citizens at birth or immigration. All participants that donated a blood 
sample signed a written informed consent form. 
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RESULTS
Women with stillbirth were more often single, cigarette smokers and pregnant with twins than 
the controls. They also had higher frequencies of medical disorders, including thyroid disease, 
diabetes and hypertension, and more often pregnancy related complications, such as 
preeclampsia, placental abruption and infants small-for-gestational-age (SGA) (Table 1). 
The main COD (Level I) according to the CODAC classification system is displayed in 
table 2. Placental causes were the most frequent COD, accounting for 50.4% of all stillbirths, 
whereas unknown COD was second in line comprising 19.4% of the cases (Table 2). 
Subclassification (Level II) revealed that two-thirds (67.4%) of the placental causes were due to
placental abruption/retroplacental hematoma or infarctions/thrombi. These two entities were 
responsible for 34% of all stillbirths and placental abruption/retroplacental hematoma alone was
the cause of 16% of all stillbirths (Digital supplement table 3). 
An AC was coded for 273/377 (72%) of all cases. The most frequent ACs were; placental 
in 92/377 (24%), cord pathologies in 51/377 (14%) and perinatal conditions in 55/377 (15 %). 
Among the cases classified as having an unknown COD, 59/73 (81%) had ACs; 26 (36%) a 
placental condition, 10 (14%) a cord condition, 10 (14%) a perinatal condition, 5 (7%) a 
maternal condition and 5 (7%) an associated maternal condition. A placental AC was assigned to 
68 (18%) of the cases with a non-placental COD. Thus 258/377 (68%) of all cases had either a 
placental COD or placental ACs.
Prevalences of demographic and clinical risk factors among women with stillbirths and 
the controls are displayed in table 1 and the aORs of the risk factor analyses in table 3. Smoking 
and SGA were significant risk factors in all causal groups. The other significant risk factors 
differed by causal group. Twin pregnancy, hypertension and diabetes (pre-gestational and 
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gestational) were significant risk factors in both the placenta and unknown groups, but not 
among women with stillbirth of other causes. Placental abruption was a significant risk factor in 
the group of placental causes only, and single civil status only in the group of other causes. 
Thyroid diseases were associated with stillbirths of placental causes and of other causes.  
The 105 cases who donated blood-samples for the biomarker study were equally 
distributed into the main COD groups as the whole study-population, 48% in the group of 
placental causes and 20% with an unknown cause. The prevalences of thrombophilia by different 
groups of COD are displayed in table 4 and the ORs for the association of thrombophilia and 
stillbirth in table 5. The F2 rs179963 (prothrombin polymorphism) was more prevalent among 
women with placental COD and other causes, but statistically significant only in the group of 
placental causes (OR 5.7; 95% CI 1.4-23.8). The prevalence of F5 rs6025 (factor V Leiden) was 
double among women with placenta or unknown COD compared to the controls, although this 
did not reach statistical significance. Inherited thrombophilia, a composite result, was 
significantly more prevalent among women with placental causes of stillbirth (OR 2.2; 95% CI 
1.0-4.7). On the other hand being positive for any one of the antiphospholipid antibodies was 
associated with a history of stillbirth of other causes (OR 3.3; 95% CI 1.1-9.9). Similar 
proportions in all COD groups, 4.0-5.9%, of women were LA-positive as compared to 1.1% of 
the controls. However, the association did not reach significance in any separate causal group, 
although the ORs in the different groups were in the range 3.6 – 5.4 (Table 5).
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DISCUSSION
In an unselected population of women, we found that more than half of all stillbirths were caused 
by or associated with placental conditions (68.4%) similar to findings of two recently published 
studies (13,14). Korteweg et al. reported 64.9% of deaths to be caused by placental pathology
and stated that classifications without or with minimal subdivision of a placental group were not 
useful in modern perinatal audit (14). Placental insufficiency probably originates early in 
pregnancy (15) and complications in late pregnancy may be determined by impaired placental 
function established already in the first 10 weeks (16). The distribution of women in other causal 
groups was in agreement with other recent reports (13,17).
The cause was unknown in 20% of the cases. A recent study of stillbirths in 6 high-
income countries reported 30% with unknown causes and claimed the main reason to be 
inadequately investigated cases (13). The reported numbers of unexplained stillbirths ranges 
from 9-71% (2,18,19), dependent on the sources of information available and the classification 
system used (20,21). Systems capable of retaining detailed information have a lower proportion 
of unexplained deaths (3,4). A comparison of 6 classification systems found CODAC to have the 
highest score regarding the ability to retain important information (2). The importance of 
placental histology has been demonstrated (2,20,22) and may lead to lower proportions of 
unexplained stillbirths (20).
Smoking was equally frequent in all causal groups. Placenta pathology has been 
suggested as a pathway for the association of smoking and stillbirth (23,24), which is not 
compatible with our results. We registered smoking habits at first antenatal visit only, but 
smoking habits could have changed later in pregnancy which might have affected the results. 
Studies suggest that women who reduce or quit smoking in the first trimester have a comparable 
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risk of stillbirth as non-smokers (25). Stillborn infants were more often SGA compared to live-
born unrelated to the cause of death. Fetal growth restriction is reported to be the factor most 
often associated with stillbirths and is probably a sign of a variety of conditions that may lead to 
fetal death (18,20). Whether it is a marker of placental insufficiency or causally associated with 
the mechanism of death is unclear (26).
Twin pregnancy, hypertension and diabetes were risk factors for stillbirths of both 
placental and unknown causes. Finding these risk factors in both groups can, in the case of 
unknown causes, suggest that data was inadequate to place them in the placenta group or that 
subtle placental pathologies found were more severe than assumed. Placenta pathology is 
assumed to be the origin of pregnancy related hypertensive disorders (27) and fetal and maternal 
complications are more frequent in twin pregnancies, especially monozygotic twins, in addition 
to unique complications as twin-twin transfusion syndrome (28,29). There was a strong 
association between diabetes and stillbirth of unknown causes. The mechanism of fetal death in 
diabetes is unknown, but alterations in fetal carbohydrate metabolism and uteroplacental 
insufficiency secondary to vascular disease are possible explanations (30).
Inherited thrombophilia combined and F2 rs179963 alone were significantly associated 
with stillbirth of placental causes. This finding would be expected since the main pathogenesis of 
thrombophilia related stillbirth is assumed to be through abnormalities in placental vasculature 
(31). The prevalence of F5 rs6025 was double among women with placental or unknown COD 
compared to the controls, although this did not reach statistical significance, probably due to 
small sample size. Korteweg et al. did not find significant differences in the prevalence of
thrombophilic defects, but they compared women in different causal groups internally and not 
with live-birth controls (3). No specific placental lesions are found among women with 
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thrombophilia (32) and whether coagulation abnormalities are the causes of abnormal 
placentation or just exert an affect on a compromised placenta is not known. Similar findings at 
delivery might simply represent a final common pathway for different underlying abnormalities. 
Placental examinations from controls would have been desirable, but in the study period 
placentas were examined only on indication.  
In CODAC the assigned cause of death is a matter of expert opinion. The cases were all 
classified by one author (L.B.H.) and possibly another coder would not have agreed in all cases. 
A kappa of 0.82-0.94 has been reported for CODAC when the coding rules are extensively 
followed (1). L.B.H. is an experienced obstetrician and the placenta histological examinations 
were performed by experienced pathologists (G.T. and B.R.), so the coding is not suspected to be 
a source of large bias. The distribution in causal groups was in agreement with the distribution in 
six other high-income countries (13), which supports our findings.
Early diagnosis of placental dysfunction is a major clinical challenge. Screening tests in
low-risk groups have been demonstrated to be poor predictors of complications (33,34).
However, “placental profile” has been proposed among women in high-risk groups, with 
somewhat promising results (35).
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Figure 1. Selection of study population for the biomarker study.
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Table 1. Prevalence of demographic and clinical risk factors among women with IUFD, 
according to the main cause of death (COD) of the CODAC- classification. 
Variable All cases
N=377
COD
Placenta
N=190
COD
Unknown
N=73
COD 
Other
N=114
Controls
N=1 215
% % % % %
Age (years)
<29
30-39
	

44.6
49.9
5.6
42.6
52.1
5.3
49.3
45.2
5.5
44.7
49.1
6.1
43.6
50.5
5.8
Parity
0
1
>2
51.2
31.8
16.7
53.2
29.5
17.4
49.3
35.6
15.1
50.0
33.3
16.7
48.5
33.2
18.4
Civil status 
Married/Cohabitation
Not married/cohabiting
86.2
13.8
85.8
14.2
95.5
4.1
80.7
19.3
92.0
8.0
Assisted reproduction 1.9 2.6 2.7 0 1.7
Twin pregnancy 5.8 7.4 6.8 2.6 2.1
Hypertensive disorders
Preeclampsia/eclampsia
Hypertension
15.7
   7.2
   8.5
18.4
9.5
8.9
17.8
5.5
12.3
9.7
4.4
5.3
9.2
4.8
4.4
Diabetes
Diabetes  type 1 or 2
Gestational diabetes
   1.9
   1.6
1.1
1.1
4.1
4.1
1.8
0.9
0.4
1.0
Placental abruption 11.7 22.6 0 0.9 0.8
Placenta previa    1.3 2.1 0 0.9 0.7
Smoking (at first visit) 35.8 37.9 32.9 34.2 13.4
Small-for-gestational age 35.8 41.1 23.3 35.1 1.8
Thyroid disease 4.2 4.7 2.7 4.4 1.1
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Table 2. Cause of death (COD) – level I – according to the CODAC- classification. 
CODAC 
COD – level I
Cases
N=377
%        (n)
0-Infection 12.2 (46)
2-Intrapartum 0.5 (2)
3-Congenital anomaly 6.1 (23)
4-Fetal 2.1 (8)
5-Cord 8.0 (30)
6-Placenta 50.4 (190)
7-Maternal 1.3 (5)
8-Unknown 19.4 (73)
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 Table 3. Risk factors for cases in different causal groups according to CODAC compared to 
controls. Adjusted odds ratios (aOR) with 95% confidence intervals (CI). 
                               COD
Variable
Placenta 
         N=190
Unknown
N=73
Other
N=114
All cases
       N=377
aOR 
(95% CI)
aOR 
(95% CI)
aOR
(95% CI)
aOR 
(95% CI)
Civil status 
Not married/cohabiting
- -
2.1
(1.1-3.9)
-
Twin pregnancy 3.6
(1.3-9.4)
5.0
(1.5-16.0)
2.2
(0.6-8.0)
3.0
(1.4-6.3)
Hypertensive disorders
Preeclampsia/eclampsia
Hypertension
0.5
(0.2-1.1)
2.2
(1.0-4.8)
0.2
(0.06-1.0)
3.5
(1.5-8.0)
0.2
(0.07-0.8)
1.0
(0.3-2.9)
0.6
(0.3-1.2)
1.9
(1.1-3.4)
Diabetes 3.5
(1.1-11.3)
8.7
(3.0-25.4)
2.9
(0.8-10.8)
3.8
(1.7-8.4)
Placental abruption 42.0
(19.4-91.0)
-
1.4
(0.2-11.5)
16.1
(7.6-33.9)
Smoking (at first visit) 2.5
(1.6-3.9)
3.7
(2.1-6.6)
2.5
(1.5-4.1)
2.6
(1.9-3.8)
Small-for-gestational age 47.9
(26.6-86.1)
28.6
(12.8-63.6)
38.6
(19.9-74.8)
32.9
(20.0-54.2)
Thyroid disease 5.5
(2.0-15.6)
3.8
(0.8-18.0)
5.5
(1.7-17.6)
4.8
(2.1-11.0)
Each variable adjusted for the all the other variables in logistic regression analysis.
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Table 4. Prevalences of acquired and inherited thrombophilia by different main groups of COD.
                                  COD
Variable
All
N=105
*N = 103
% (n)
Placenta
N = 50
*N=49
% (n)
Unknown 
N = 21
*N=21
% (n)
Other
N = 34
*N=33
% (n)
Controls 
N =262
% (n)
*&F5 6025 10.7 (11) 14.3 (7) 14.3 (3) 3.0 (1) 7.6 (20)
*#F2 rs1799963 5.8 (6) 8.2 (4) 0 6.1 (2) 1.5 (4)
*Antithrombin deficiency 1.0 (1) 0 0 3.0 (1) 0
*Protein C deficiency 1.0 (1) 0 0 3.0 (1) 1.1 (3)
*Protein S deficiency 1.9 (2) 2.0 (1) 0 3.0 (1) 2.3 (6)
*Any inherited thrombophilia 18.4 (19) 22.4 (11) 14.3 (3) 15.2 (5) 11.8 (31)
Lupus anticoagulant 4.8 (5) 4.0 (2) 4.8 (1) 5.9 (2) 1.1 (3)
Anti-cardiolipin antibodies 3.8 (4) 2.0 (1) 4.8 (1) 5.9 (2) 2.3 (6)
Anti-ß2-glycoproteint 1 4.8 (5) 6.0 (3) 0 5.9 (2) 1.5 (4)
Antiphospholipid antibodies 9.5 (10) 6.0 (3) 9.5 (2) 14.7 (5) 5.0 (13)
*Any thrombophilia 27.2 (28) 28.6 (14) 23.8 (5) 27.3 (9) 16.4 (43)
*Two women reported use of warfarin and were therefore excluded from all analyzes of 
inherited thrombophilias. &Also known as factor V Leiden; #also known as the prothrombin 
gene 20210 allele variation.
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Table 5. Thrombophilic risk factors for IUFD according to COD compared to controls. 
Odds ratios (OR) and 95% confidence intervals (CI).
                                  COD
Variable
All
N = 105
*N=103
Placenta
N = 50
*N=49 
Unknown 
N = 21
*N=21 
Other
N = 34
*N=33 
OR
95% CI
OR
95% CI
OR
95% CI
OR
95% CI
*&F5 6025 1.4
(0.7-3.1)
2.0
(0.8-5.1)
2.0
(0.5-7.4)
0.4
(0.05-2.9)
*#F2 rs1799963 4.0
(1.1-14.4)
5.7
(1.4-23.8)
- 4.2
(0.7-23.7)
*Antithrombin deficiency - - - -
*Protein C deficiency 0.8
(0.09-8.2)
- - 2.7 
(0.3-26.7)
*Protein S deficiency 0.8
(0.17-4.3)
0.9
(0.1-7.6)
- 1.3
(0.2-11.4)
*Any inherited thrombophilia 1.7 
(0.9-3.1)
2.2
(1.0-4.7)
1.2
(0.3-4.5)
1.3
(0.5-3.7)
Lupus anticoagulant 4.3
(1.0-18.4)
3.6
(0.6-22.1)
4.3
(0.4-43.4)
5.4 
(0.9-33.5)
Anticardiolipin antibodies 1.7
(0.5-6.1)
0.9
(0.1-7.4)
2.1
(0.2-18.6)
2.7
(0.5-13.8)
Anti- ß2 glycoprotein 1 3.2
0.9-12.3)
4.1
(0.9-19.0)
- 4.0
(0.7-22.9)
Any antiphospholipid antibodies 2.0
(0.9-4.8)
1.2
(0.3-4.5)
2.0
(0.4-9.6)
3.3
(1.1-9.9)
Any thrombophilia 1.9
(1.1-3.3)
2.0
(1.0-4.1)
1.6
(0.6-4.6)
1.9
(0.8-4.4)
*Two women reported use of warfarin and were therefore excluded from all analyzes of 
inherited thrombophilias. &Also known as factor V Leiden; #also known as the prothrombin 
gene 20210 allele variation.
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